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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in 2013. This review is one in a series of Cochrane Reviews
investigating pair-wise monotherapy comparisons.
Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked
seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become
seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.
Worldwide, phenytoin is a commonly used antiepileptic drug. It is important to know how newer drugs, such as oxcarbazepine, compare
with commonly used standard treatments.
Objectives
To review the time to treatment failure, remission andfirst seizurewith oxcarbazepine compared to phenytoin,whenused asmonotherapy
in people with focal onset seizures or generalised tonic-clonic seizures (with or without other generalised seizure types).
Search methods
We searched the following databases on 20 August 2018: the Cochrane Register of Studies (CRS Web), which includes the Cochrane
Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946
to 20 August 2018), ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (
ICTRP). We handsearched relevant journals and contacted pharmaceutical companies, original trial investigators and experts in the
field.
Selection criteria
We included randomised controlled trials comparing monotherapy with either oxcarbazepine or phenytoin in children or adults with
focal onset seizures or generalised onset tonic-clonic seizures.
Data collection and analysis
This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure and our secondary outcomes
were time to first seizure post-randomisation, time to six-month and 12-month remission, and incidence of adverse events. We used
Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs) with 95% confidence intervals
(CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.
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Main results
Individual participant data were available for 480 out of a total of 517 participants (93%), from two out of three included trials. For
remission outcomes, a HR of less than one indicated an advantage for phenytoin; and for first seizure and treatment failure outcomes,
a HR of less than one indicated an advantage for oxcarbazepine.
The results for time to treatment failure for any reason related to treatment showed apotential advantage of oxcarbazepine over phenytoin,
but this was not statistically significant (pooled HR adjusted for epilepsy type: 0.78 95% CI 0.53 to 1.14, 476 participants, two trials,
moderate-quality evidence). Our analysis showed that treatment failure due to adverse events occurred later on with oxcarbazepine
than phenytoin (pooled HR for all participants: 0.22 (95% CI 0.10 to 0.51, 480 participants, two trials, high-quality evidence). Our
analysis of time to treatment failure due to lack of efficacy showed no clear difference between the drugs (pooled HR for all participants:
1.17 (95% CI 0.31 to 4.35), 480 participants, two trials, moderate-quality evidence).
We found no clear or statistically significant differences between drugs for any of the secondary outcomes of the review: time to first
seizure post-randomisation (pooled HR adjusted for epilepsy type: 0.97 95% CI 0.75 to 1.26, 468 participants, two trials, moderate-
quality evidence); time to 12-month remission (pooled HR adjusted for epilepsy type 1.04 95% CI 0.77 to 1.41, 468 participants, two
trials, moderate-quality evidence) and time to six-month remission (pooled HR adjusted for epilepsy type: 1.06 95% CI 0.82 to 1.36,
468 participants, two trials, moderate-quality evidence).
Themost common adverse events reported inmore than 10% of participants on either drug were somnolence (28% of total participants,
with similar rates for both drugs), headache (15% of total participants, with similar rates for both drugs), dizziness (14.5% of total
participants, reported by slightly more participants on phenytoin (18%) than oxcarbazepine (11%)) and gum hyperplasia (reported by
substantially more participants on phenytoin (18%) than oxcarbazepine (2%)).
The results of this review are applicable mainly to individuals with focal onset seizures; 70% of included individuals experienced seizures
of this type at baseline. The two studies included in IPD meta-analysis were generally of good methodological quality but the design of
the studies may have biased the results for the secondary outcomes (time to first seizure post-randomisation, time to six-month and 12-
month remission) as seizure recurrence data were not collected following treatment failure or withdrawal from the study. In addition,
misclassification of epilepsy type may have impacted on results, particularly for individuals with generalised onset seizures.
Authors’ conclusions
High-quality evidence provided by this review indicates that treatment failure due to adverse events occurs significantly later with
oxcarbazepine than phenytoin. For individuals with focal onset seizures, moderate-quality evidence suggests that oxcarbazepine may be
superior to phenytoin in terms of treatment failure for any reason, seizure recurrence and seizure remission. Therefore, oxcarbazepine
may be a preferable alternative treatment than phenytoin, particularly for individuals with focal onset seizures. The evidence in this
review which relates to individuals with generalised onset seizures is of low quality and does not inform current treatment policy.
We recommend that future trials should be designed to the highest quality possible with regards to choice of population, classification
of seizure type, duration of follow-up (including continued follow-up after failure or withdrawal of randomised treatment), choice of
outcomes and analysis, and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Oxcarbazepine versus phenytoin monotherapy (single medication treatment) for epilepsy
This is an updated version of the Cochrane Review first published in Issue 2, 2006 of the Cochrane Database of Systematic Reviews.
Background
Epilepsy is a common disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied two types
of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and move
throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole hemisphere
of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation) and move from one part
of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control generalised
onset or focal onset seizures.
Objective
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Worldwide, phenytoin is a commonly used antiepileptic medication and oxcarbazepine is one of a newer generation of antiepileptic
medications. The aim of this review was to compare how effective these medications are at controlling seizures, to find out if they are
associated with side effects that may result in individuals stopping themedication, and to help people choose between thesemedications.
Methods
We assessed the evidence from three studies (specifically, randomised controlled trials) comparing oxcarbazepine with phenytoin. We
were able to combine information for 480 people from two of the three trials. For the remaining 37 people from one trial, information
was not available to use in this review. The evidence is current to 20 August 2018.
Results
The review found that people taking oxcarbazepine stop taking treatment because of side effects significantly later than people taking
phenytoin. Our results also showed that people with focal onset seizures taking phenytoin may stop taking treatment for any reason
earlier than people with focal onset seizures taking oxcarbazepine. The results also suggest that people with focal onset seizures taking
oxcarbazepine may experience a repeat seizure later, and achieve freedom from seizures earlier, than people with focal onset seizures
taking phenytoin. There was no clear difference between the drugs in terms of withdrawal from the treatment, seizure recurrence and
seizure remission for individuals with generalised onset seizures.
Quality of the evidence
The two studies included in analysis were well designed but no information about seizures was recorded after people stopped taking
their trial medication, which may have impacted on the results of the study.
Most people (70%) included in the studies within this review had focal onset seizures, so the results are mainly relevant to people with
this epilepsy type. Also up to 30% of the people in the trials used in our results may have been wrongly classified as having generalised
seizures, which may have impacted on the results.
For these reasons, we judged the quality of the evidence provided by this review to be of moderate quality for people with focal onset
seizures, and low quality for people with generalised onset seizures.
Conclusions
For people with focal onset seizures, oxcarbazepine may be a preferable treatment to phenytoin, but more information is needed for
people with generalised onset seizures to choose between these medications. We recommend that all future trials comparing these
medications, or any other antiepileptic medications, should be designed using high-quality methods. Seizure types of people included
in trials should also be classified very carefully.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oxcarbazepine compared with phenytoin for epilepsy
Patient or population: adults and children with newly diagnosed epilepsy
Settings: outpat ients
Intervention: oxcarbazepine
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Oxcarbazepine
Time to treatment fail-
ure (any reason related
to treatment)
All participants
Range of follow-up: 1 to
779 days
The 20th percent ile* *
of t ime to treatment
failure was 263 days in
the phenytoin group
The 20th percent ile* *
of t ime to treatment
failure was 342 days
(79 days longer) in the
oxcarbazepine group
HR 0.78
(0.53 to 1.14)a
476
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: focal onset
seizures
Range of follow-up: 1 to
532 days
The 20th percent ile* *
of t ime to treatment
failure was 230 days in
the phenytoin group
The 20th percent ile* *
of t ime to treatment
failure was 414 days
(184 days longer) in the
oxcarbazepine group
HR 0.69
(0.43 to 1.09)
333
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: generalised on-
set seizures
Range of follow-up: 1 to
779 days
The 20th percent ile* *
of t ime to treatment
failure was 306 days in
the phenytoin group
The 20th percent ile* *
of t ime to treatment
failure was 268 days
(38 days shorter) in the
oxcarbazepine group
HR 1.03
(0.51 to 2.08)
143
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
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Time to treatment fail-
ure due to adverse
events
All participants
Range of follow-up: 1 to
779 days
32 out of 240 (13%)
withdrew due to ad-
verse events in the
phenytoin groupc
7 out of 240 (3%) with-
drew due to adverse
events in the oxcar-
bazepine groupc
HR 0.22
(0.10 to 0.51)
480
(2 trials)
⊕⊕⊕⊕
high
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
Time to treatment fail-
ure due to lack of effi-
cacy
All participants
Range of follow-up: 1 to
779 days
4 out of 240 (2%) with-
drew due to lack of ef -
f icacy in the phenytoin
groupc
5 out of 240 (2%) with-
drew due to lack of ef -
f icacy in the phenytoin
groupc
HR 1.17
(0.31 to 4.35)
480
(2 trials)
⊕⊕⊕©
moderated
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
* Illustrat ive risks in the oxcarbazepine and phenytoin groups are calculated at the median t ime to treatment failure (i.e. the t ime to 50% of part icipants failing or withdrawing
f rom allocated treatment) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime to treatment failure’ between the
treatment groups
* * The 20th percent ile of t ime to treatment failure (i.e. the t ime to 20% of part icipants failing or withdrawing f rom allocated treatment) is presented for the subgroup with
generalised seizures as less than 50% of part icipants failed/ withdrew f rom treatment in both groups, therefore the median t ime could not be calculated
Abbreviations: 95% CI: 95% conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a. Pooled hazard rat io for all part icipants adjusted for epilepsy type.
b. Downgraded once due to risk of bias: up to 29%of adult part icipants classif ied as experiencing generalised onset seizures
(in Bill 1997) may have had their epilepsy type wrongly classif ied and sensit ivity analyses show that m isclassif icat ion may
have had an impact on the conclusions drawn for individuals with generalised seizures and whether an interact ion between
treatment ef fect and epilepsy type exists.
c. Medians or 20th percent ile of t ime to treatment failure could not be calculated due to small numbers of part icipants
withdrawing due to adverse events or lack of ef f icacy in one or both of the treatment groups. We were unable to perform
subgroup analysis for ’t ime to treatment failure due to adverse events’ and ’t ime to treatment failure due to lack of ef f icacy’
due to small numbers of part icipants with each epilepsy type failing treatment for these reasons.
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d. Downgraded once due to imprecision: there are wide conf idence intervals around the pooled HR so it is unclear whether
there is an advantage to either drug, or no dif ference between drugs.
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B A C K G R O U N D
This is an updated version of the original Cochrane Review
published in 2006 (Muller 2006), and updated in 2013 (Nolan
2013a).
Description of the condition
Epilepsy is a common neurological condition in which recurrent,
unprovoked seizures are caused by abnormal electrical discharges
from the brain. Epilepsy is a disorder ofmany heterogenous seizure
types, with an estimated incidence of 33 to 57 per 100,000 person-
years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000;
Olafsson 2005; Sander 1996), accounting for approximately 1%
of the global burden of disease (Murray 1994). The lifetime risk
of epilepsy onset is estimated to be 1300 to 4000 per 100,000 per-
son years (Hauser 1993; Juul-Jenson 1983) and the lifetime preva-
lence could be as much as 70 million people worldwide (Ngugi
2010). It is believed that with effective drug treatment, up to 70%
of individuals with active epilepsy have the potential to become
seizure free and go into long-term remission shortly after starting
drug therapy (Cockerell 1995; Hauser 1993; Sander 2004), and
that around 70% of individuals can achieve seizure freedom us-
ing a single antiepileptic drug (AED) in monotherapy (Cockerell
1995). Current guidelines from the National Institute for Health
and Care Excellence (NICE) recommend that both adults and
children with epilepsy should be treated with monotherapy wher-
ever possible (NICE 2012). The remaining 30% of individuals
experience refractory or drug resistant seizures which often require
treatment with combinations of antiepileptic drugs (AEDs) or al-
ternative treatments such as epilepsy surgery (Kwan 2000).
We will study two seizure types in this review: generalised onset
seizures, in which electrical discharges begin in one part of the
brain and move throughout the brain; and focal onset seizures, in
which the seizure is generated in and affects one part of the brain
(the whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Oxcarbazepine is one of the newer antiepileptic drugs and has sim-
ilar chemical properties to its parent compound carbamazepine. It
is licensed in a number of countries for use as both monotherapy
and add-on (adjunctive) therapy.
Whenused asmonotherapy, oxcarbazepine has been shown tobe as
effective in terms of seizure control as first-line antiepileptic drugs
carbamazepine (Dam 1989), phenytoin (Bill 1997; Guerreiro
1997) and sodium valproate (Christe 1997). Oxcarbazepine is
generally well tolerated as monotherapy in adults (Beydoun 2000;
Bill 1997; Dam 1989 Christe 1997; Schachter 1999) and children
(Guerreiro 1997). It has been shown to have a low incidence of
cosmetic side effects and serious adverse events such as allergic re-
actions (Kwan 2003), resulting in significantly lower discontinua-
tion rates compared to carbamazepine in adults (Dam 1989), and
phenytoin in adults (Bill 1997) and children (Guerreiro 1997).
Common adverse events, reported in more than 5% of partici-
pants receiving oxcarbazepine monotherapy, are similar in adults
and children and include somnolence, headache, dizziness, nausea,
vomiting, fatigue and rash (Bang 2003; Kwan 2003; Wellington
2001). Oxcarbazepine has been shown to be better tolerated than
phenytoin in adults (particularly in terms of gum hyperplasia,
tremor, diplopia and nystagmus (Bill 1997)), and in children (par-
ticularly in terms of gum hyperplasia, nervousness, dizziness, hy-
pertrichosis and ataxia (Guerreiro 1997)).
Worldwide, phenytoin is a commonly used antiepileptic drug for
participants with focal onset seizures and generalised onset tonic-
clonic seizures. Although phenytoin is no longer considered as a
first-line treatment inEurope (Wallace 1997), it ismore commonly
used in the USA (Wilder 1995). Phenytoin is associated with
long-term cosmetic changes including gum hypertrophy, acne and
coarsening of the facial features (Mattson 1985; Scheinfeld 2003),
as well as low folic acid levels, predisposing participants to mega-
loblastic anaemia (Carl 1992). It can also cause a rash (Tennis
1997) in 5% to 10% of participants, which on rare occasions may
be life threatening. It is also associated with congenital abnormal-
ities (Gladstone 1992; Nulman 1997), where the risk is estimated
to be two to three times that of the general population (Meador
2008). Phenytoin is also particularly associated with fetal hydan-
toin syndrome (Scheinfeld 2003).
How the intervention might work
Antiepileptic drugs suppress seizures by reducing neuronal ex-
citability, hence reducing the probability that a seizure will occur.
Oxcarbazepine and phenytoin are broad spectrum treatments suit-
able for many seizure types, and both have an anticonvulsant
mechanism through blocking ion channels, binding with neu-
rotransmitter receptors or through inhibiting the metabolism or
reuptake of neurotransmitters and the modulation of gamma-
aminobutyric acid-A (GABA-A) receptors (Faigle 1990; Granger
1995; Grant 1992; Ragsdale 1991; Willow 1985).
Why it is important to do this review
With evidence that up to 70% of individuals with a new epilepsy
diagnosis enter a long-term remission of seizures shortly after start-
ing drug therapy (Cockerell 1995; Hauser 1993; Sander 2004),
the correct choice of first-line antiepileptic therapy for individuals
with newly diagnosed seizures is of great importance. It is impor-
tant to know how newer drugs, such as oxcarbazepine, compare
with first-line standard treatments. Our aim in this systematic re-
view is to overview existing evidence for the comparative efficacy
and tolerability of oxcarbazepine and phenytoin (one of the stan-
dard antiepileptic drugs) when used as monotherapy.
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There are difficulties in undertaking a systematic review of
epilepsy monotherapy trials as the important efficacy outcomes
require analysis of time-to-event data (for example, time to first
seizure after randomisation). Although methods have been devel-
oped to synthesise time-to-event data using summary informa-
tion (Parmar 1998; Williamson 2002), the appropriate statistics
are not commonly reported in published epilepsy trials (Nolan
2013b; Williamson 2000). Furthermore, although most epilepsy
monotherapy trials collect seizure data, there has been no uni-
formity in the definition and reporting of outcomes. For exam-
ple, trials may report time to 12-month remission but not time
to first seizure or vice versa, or some trials may define time to
first seizure from the date of randomisation while others use the
date of achieving maintenance dose. Trial investigators have also
adopted differing approaches to the analysis, particularly with
respect to the censoring of time-to-event data. For these rea-
sons, we performed this review using individual participant data
(IPD), which helps to overcome these problems. This review is
one in a series of Cochrane IPD reviews investigating pair-wise
monotherapy comparisons (Marson 2000; Nevitt 2017b; Nevitt
2018a; Nevitt 2018b; Nolan 2013c; Nevitt 2018c; Nolan 2016b).
These data have also been included in IPD network meta-analy-
ses of antiepileptic drug monotherapy (Tudur Smith 2007; Nevitt
2017a)
O B J E C T I V E S
To review the time to treatment failure, remission and first
seizure with oxcarbazepine compared to phenytoin, when used as
monotherapy in people with focal onset seizures or generalised
tonic-clonic seizures (with or without other generalised seizure
types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) which used ei-
ther an adequate method of allocation concealment (e.g. sealed
opaque envelopes) or a ’quasi’ method of randomisation (e.g. al-
location by date of birth).
Studies may have been double-blind, single-blind, or unblinded.
Studies must have included a comparison of oxcarbazepine
monotherapy versus phenytoin monotherapy in individuals with
epilepsy.
Types of participants
We included children or adults with focal onset seizures (simple fo-
cal, complex focal or secondarily generalised tonic-clonic seizures)
or generalised onset tonic-clonic seizures, with or without other
generalised seizure types (in other words, those who had only gen-
eralised tonic-clonic seizures and those who had both generalised
onset tonic-clonic seizures and generalised seizures of other types,
e.g. absence, myoclonic, etc.).
We excluded individuals with other generalised seizure types alone
without generalised tonic-clonic seizures (e.g. those who had only
absence seizures without any generalised tonic-clonic seizures) due
to differences in first-line treatment guidelines for other gener-
alised seizure types (NICE 2012).
We included individuals with a new diagnosis of epilepsy, or
those who have had a relapse following withdrawal of antiepileptic
monotherapy.
Types of interventions
Oxcarbazepine or phenytoin as monotherapy.
Types of outcome measures
Below is a list of outcomes investigated in this review. Reporting
of these outcomes in the original trial report was not an eligibility
requirement for inclusion in this review.
Primary outcomes
Time to treatment failure (retention time). This was a combined
outcome reflecting both efficacy and tolerability, as the following
may have lead to failure of treatment: continued seizures, side ef-
fects, non-compliance or the initiation of add-on treatment. This
is an outcome to which the participant makes a contribution and
is the primary outcome measure recommended by the Commis-
sion on Antiepileptic Drugs of the International League Against
Epilepsy (ILAE 1998; ILAE 2006).
Time to treatment failure is considered according to three defini-
tions:
1. time to treatment failure for any treatment related reason
(continued seizures, side effects, non-compliance or the
initiation of add-on treatment);
2. time to treatment failure due to adverse events (i.e. side
effects);
3. time to treatment failure due to lack of efficacy (i.e.
continued seizures).
Secondary outcomes
1. Time to first seizure post-randomisation
2. Time to achieve 12-month remission (seizure-free period)
3. Time to achieve six-month remission (seizure-free period)
4. Incidence of adverse events (all reported whether related or
unrelated to treatment)
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Search methods for identification of studies
Electronic searches
Searches were run for the original review in 2006 and subsequent
searches were run in April 2008, July 2010, November 2011, June
2012, January 2013, and February 2015.
For the latest update we searched the following databases on 20
August 2018, with no language restrictions.
1. The Cochrane Register of Studies (CRS Web), which
includes the Cochrane Epilepsy Group Specialized Register and
the Cochrane Central Register of Controlled Trials
(CENTRAL), using the strategy outlined in Appendix 1.
2. MEDLINE (Ovid, 1946 to 20 August 2018), using the
strategy outlined in Appendix 2.
3. ClinicalTrials.gov, using the strategy outlined in Appendix
3.
4. The World Health Organization ( WHO) International
Clinical Trials Registry Platform ( ICTRP), using the strategy
outlined in Appendix 4.
Searching other resources
In addition, we handsearched relevant journals, reviewed the refer-
ence lists of included studies to search for additional reports of rele-
vant studies, contacted Novartis (manufacturers of oxcarbazepine)
and Parke-Davis (manufacturers of phenytoin) and researchers in
the field to seek any ongoing or unpublished studies.
Data collection and analysis
Selection of studies
Two of the authors (MM and SJN) independently assessed all
identified trials for inclusion. Any disagreements were resolved by
mutual discussion.
Data extraction and management
We requested the following IPD for all trials meeting our inclusion
criteria.
Trial methods
1. Method of generation of random list
2. Method of concealment of randomisation
3. Stratification factors
4. Blinding methods
Participant covariates
1. Gender
2. Age
3. Seizure types
4. Time between first seizure and randomisation
5. Number of seizures prior to randomisation (with dates)
6. Presence of neurological signs
7. Electroencephalographic (EEG) results
8. Computerised tomography/magnetic resonance imaging
(CT/MRI) results
Follow-up data
1. Treatment allocation
2. Date of randomisation
3. Dates of follow-up
4. Dates of seizures post-randomisation or seizure frequency
data between follow-up visits
5. Dates of treatment failure and reasons for treatment failure
6. Dose
7. Dates of dose changes
For each trial for which we did not obtain IPD, we carried out
an assessment to see whether any relevant aggregate level data had
been reported or could be indirectly estimated using the methods
of Parmar 1998 and Williamson 2002.
For included trials with IPDprovided (Bill 1997;Guerreiro 1997),
seizure data were provided in terms of themean number of seizures
recorded per week in the titration period (first eight weeks) and the
maintenance period (following 48weeks) rather than specific dates
of seizures. To enable time-to-event outcomes to be calculated,
we applied linear interpolation to approximate the days on which
seizures occurred. For example, if the mean number of seizures
per week in the titration period was 0 and in the maintenance
period it was 0.02115, and the participant started treatment on
28 September 1993 and ended treatment on 19 October 1994
(interval of 387 days), then the date of first seizure would be ap-
proximately 165.5 days after the start of the maintenance period
and thus 221.5 days after the start of treatment. This allowed an
estimate of the time to six- and 12-month remission and the time
to first seizure to be computed.
We calculated time to first seizure from the date of randomisation
to the date that their first seizure was estimated to have occurred.
If the mean number of seizures per week data were missing for the
titration period (first eight weeks), the estimated time of the first
seizure could not be calculated. Eight participants in total (five in
Bill 1997, and three in Guerreiro 1997) had missing seizure data
for the titration period (all eight also had missing seizure data for
the maintenance period). The number of days on trial medication
ranged between one and 36 days for these eight participants. We
excluded them from analyses of time to first seizure, time to six-
month remission and time to 12-month remission, but included
them in the analysis of time to treatment failure.
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We calculated time to six- and 12-month remission from the date
of randomisation to the date (or estimated date) the individual
had first been free from seizures for six or 12 months respectively.
If the participant had one or more seizures in the titration period,
a six- or 12-month seizure-free period could also occur between
the estimated date of the last seizure in the titration period and
the estimated date of the first seizure in the maintenance period.
If themean ’number of seizures per week’ data weremissing for the
maintenance period (but not for the titration period), the values
for six- and 12-month remission would be censored at the end of
the titration period (effectively excluding them from the analysis).
These outcomeswere also censored if the individual died or follow-
up ceased prior to the occurrence of the event of interest.
For both trials (Bill 1997; Guerreiro 1997), the date of and rea-
son for the treatment failure were provided directly (see Table 1
for reasons of premature discontinuation of treatment). Time to
treatment failure was calculated as date of randomisation to date of
treatment failure. For the analysis of time-to-event, we defined an
’event’ as treatment failure because of reasons related to the treat-
ment (i.e. lack of efficacy, adverse events, or both lack of efficacy
and adverse events), non-compliance with the treatment regimen,
withdrawal of consent from the trial, etc.). We censored the out-
come if treatment failure or withdrawal of treatment was for rea-
sons not related to the trial treatment, i.e. loss to follow-up, death
(not treatment or epilepsy related), withdrawal of treatment due to
remission, etc.We also censored individuals who were still on allo-
cated treatment at the date of the end of follow-up. We considered
documented reasons for treatment failure or treatment withdrawal
on a case-by-case basis for relation to treatment; three of the review
authors (SJN, MM and AGM) independently classified reasons
for treatment failure as ’events’ or ’censored’ and resolved any dis-
agreements by discussion. We extracted detail about the reason for
the treatment failure from study case report forms when necessary,
e.g. for death and protocol violation(s). Two deaths were recorded.
One was classified as a censored value, because the cause of death
was unrelated to the treatment or the condition. The other death
was classified as an event: the participant died after experiencing
an episode of status epilepticus, but had been non-compliant and
discontinued treatment before they died.
For the analysis of ’time to treatment failure due to adverse events’,
only treatment failures which were documented to be due to ad-
verse events (either as a sole reason or due to both a lack of efficacy
and adverse events) were classed as an ’event’ within time-to-event
analyses and all other reasons for treatment failure were censored.
Similarly, for the analysis of ’time to treatment failure due to lack of
efficacy’ only treatment failures which were documented to be due
to lack of efficacy (i.e. continued seizures, either as a sole reason or
due to both a lack of efficacy and adverse events) were classed as
an ’event’ within time-to-event analyses and all other reasons for
treatment failure were censored.
Assessment of risk of bias in included studies
Two review authors (SJN and MM) independently assessed the
risk of bias for each trial using the Cochrane ’Risk of bias’ tool,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We rated each of the following six
domains as low, unclear or high risk of bias: method of generat-
ing random sequence, allocation concealment, blinding methods
(blinding of participants and personnel and blinding of outcome
assessment), incomplete outcome data, selective outcome report-
ing and other sources of bias. Any discrepancies in ’Risk of bias’
judgements of the two review authors were resolved by discussion.
In the event of the presence of high risk of bias in included trials
(due to inadequate allocation concealment or lack of blinding),
we planned to perform sensitivity analyses excluding these trials.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes with the hazard ratio (HR) and 95% confidence interval
(CI) used as the measure of treatment effect. We calculated out-
comes from IPD provided, where possible, or extracted from pub-
lished trials if possible.
Unit of analysis issues
We did not have any unit of analysis issues. The unit of allocation
and analysis was the individual for all included trials; and no trials
included in meta-analyses were of a repeated measures (longitudi-
nal) nature or of a cross-over design.
Dealing with missing data
For each trial that supplied IPD, we reproduced results from trial
results where possible and performed the following consistency
checks.
1. We cross-checked trial details against any published report
of the trial and contacted original trial authors if we found
missing data, errors or inconsistencies. If trial authors could not
resolve inconsistencies between the IPD and the published data,
depending on the extent of the inconsistencies, we planned to
perform sensitivity analysis or we excluded the data from the
meta-analysis.
2. We reviewed the chronological randomisation sequence and
checked the balance of prognostic factors, taking account of
factors stratified for in the randomisation procedure.
Assessment of heterogeneity
Weassessed heterogeneity statistically using theQ test (P <0.10 for
significance) and the I² statistic (where a value of greater than 50%
indicates considerable heterogeneity; Higgins 2003), and visually
by inspecting forest plots.
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Assessment of reporting biases
Two review authors (SJN and MM) undertook a full quality and
’Risk of bias’ assessment. In theory, a review using IPD should
overcome issues of reporting biases as unpublished data can be
provided and unpublished outcomes calculated.
Data synthesis
We aimed to carry out our analysis on an intention-to-treat basis
(that is, where participants are analysed in the group to which they
were randomised, irrespective of which treatment they actually re-
ceived). However, in the two trials included in meta-analysis, par-
ticipants were not followed up after treatment failure or treatment
withdrawal (see Table 1 for reasons for premature discontinuation
of treatment). For most of these participants, the reason for treat-
ment failure classed as an event for the analysis of time to treat-
ment failure, and these participants had to be censored at the time
of treatment failure for the seizure outcomes, which contravenes
the principle of intention-to-treat.
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the antiepileptic drugs
(AEDs). We used Cox proportional hazards regression models to
obtain trial-specific estimates of log (hazard ratio) or treatment
effect and associated standard errors in Stata Statistical Software,
version 14 (Stata 2015). The model assumes that the ratio of haz-
ards (risks) between the two treatment groups is constant over time
(i.e. hazards are proportional). We tested this proportional hazards
assumption of the Cox regression model for each outcome of each
trial by testing the statistical significance of a time varying covari-
ate in the model. We evaluated overall pooled estimates of hazard
ratios (with 95% confidence intervals) using the generic inverse
variance method. We expressed results as hazard ratios (HRs) and
95% confidence interval (CIs).
By convention, a HR greater than one indicates that an event is
more likely to occur earlier on oxcarbazepine than on phenytoin.
Hence, for time to treatment failure or time to first seizure, a HR
greater of less one indicates a clinical advantage for oxcarbazepine
(e.g. HR = 0.8 would suggest a 20% reduction in hazard of treat-
ment failure from oxcarbazepine compared to phenytoin), and for
time to achieve six-month and 12-month remission, a HR of less
than one indicates a clinical advantage for phenytoin.
We anticipated that adverse events may have been recorded using
different methods and reported in different levels of detail across
included studies, therefore we did not analyse incidence of adverse
events and instead reported this data narratively.
Subgroup analysis and investigation of heterogeneity
Due to the strong clinical belief that some antiepileptic drugs
are more effective in some seizure types than others, we stratified
all analyses by seizure type (focal onset versus generalised onset),
according to the classification of main seizure type at baseline. We
classified focal seizures (simple or complex) and focal secondarily
generalised seizures as focal epilepsy.
We classified primarily generalised seizures as generalised epilepsy.
We conducted a Chi² test of interaction between treatment and
seizure type. If we found significant statistical heterogeneity to be
present, we performedmeta-analysis with a random-effects model
in addition to a fixed-effect model, presenting the results of both
models and performing sensitivity analyses to investigate differ-
ences in study characteristics.
Sensitivity analysis
1. The two trials which provided IPD were double-blind.
After completion of the maintenance period, some participants
continued to be followed up taking ’open-label’ (unblinded)
treatment. The primary analyses included data from this open-
label period. We repeated the analysis, including only data from
the double-blind period of 392 days (eight-week titration period
plus the 48-week maintenance period).
2. Misclassification of seizure type is a recognised problem in
epilepsy, whereby some people with generalised seizures have
been mistakenly classed as having focal onset seizures, and vice
versa. There is clinical evidence that individuals with generalised
onset seizures are unlikely to have an ’age of onset’ greater than
25 to 30 years (Malafosse 1994). Such misclassification impacted
upon the results of three reviews in our series of pair-wise reviews
for monotherapy in epilepsy comparing carbamazepine to
phenobarbitone, phenytoin and sodium valproate, in which
around 30% to 50% of participants analysed may have had their
seizure type misclassified as generalised onset (Marson 2000;
Nevitt 2018b; Nevitt 2017b). Given the potential biases
introduced into those reviews, we examined the distribution of
age at onset for individuals with generalised seizures in the trials
included in this review, to assess the potential impact of
misclassification of seizure type on the outcomes.
One trial was a paediatric trial so no individuals over the age of
30 were recruited (Guerreiro 1997). In Bill 1997, 104 individu-
als were classified as having generalised onset seizures and 30 of
these individuals were over the age of 30 at entry into the trial.
Therefore, up to 29% of individuals classified as having gener-
alised onset seizures may have had their seizure type misclassified.
Such a misclassification could bias our results against finding an
interaction between treatment and seizure types (focal onset versus
generalised onset). We undertook the following two analyses to
investigate misclassification.
1. We reclassified all individuals with generalised seizures and
age at onset greater than 30 into an ’uncertain seizure type’
group.
2. We reclassified individuals with generalised seizures and age
at onset greater than 30 as having focal onset seizures.
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Summary of findings and quality of the evidence
(GRADE)
For the 2013 update, in a post-hoc change from protocol, we
added two ’Summary of findings’ tables to the review (outcomes in
the tables were decided before the update started based on clinical
relevance).
Summary of findings for themain comparison reports the primary
outcome of ’time to treatment failure (for any reason related to
treatment)’ and ’time to treatment failure due to adverse events’ in
the subgroups of participants with focal onset seizures, generalised
onset seizures and overall adjusted by epilepsy type.
Summary of findings 2 reports the secondary outcomes of ’time
to first seizure’ and ’time to 12-month remission’ in the subgroups
of participants with focal onset seizures, generalised onset seizures
and overall, adjusted by epilepsy type.
We determined the quality of the evidence using the GRADE
approach, where we downgraded our assessment in the presence
of high risk of bias in at least one trial, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results
and high probability of publication bias.We downgraded evidence
by one level if the limitation was considered serious and by two
levels if considered very serious, as judged by the review authors.
R E S U L T S
Description of studies
Results of the search
We identified 125 records from the databases and search strate-
gies outlined in Electronic searches. We found no further records
through searching other resources. We removed 36 duplicate
records and screened 89 records (title and abstract) for inclusion
in the review. We excluded 80 records based on title and abstract
and assessed eight full-text articles and records for inclusion in the
review. One study was excluded from the review and three studies
(reported in seven full-text articles) were included in the review.
We identified no new studies in this update of the review. See
Figure 1 for details of eligibility screening.
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Figure 1. PRISMA Study flow diagram.
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Included studies
We included a total of three randomised controlled trials in which
participants were randomised to oxcarbazepine or phenytoin; see
Characteristics of included studies for further details.
Individual participant data (IPD) were available for a total of 480
participants from two studies (Bill 1997; Guerreiro 1997), and
computerised data were provided directly for both trials. Data
were available for the following percentages of participants, on
the following characteristics: randomised drug (100%); time be-
tween first seizure and randomisation (100%); number of seizures
prior to randomisation (100%); sex (100%); age (99.8%); seizure
types (99.2%); electroencephalographic (EEG) results (98.1%);
and computerised tomography (CT) scan results (79.2%). Neu-
rological examination findings were not available for either trial.
See the Characteristics of included studies and Table 2 for further
details.
The two trials were similar in design and recruited participants
with newly diagnosed and previously untreated epilepsy, however
one trial recruited adults only (Bill 1997), and one trial recruited
children and adolescents only (Guerreiro 1997), which is a po-
tential source of heterogeneity. Both trials recruited participants
with focal onset seizures (simple/complex focal or secondary gener-
alised tonic-clonic) and participants with generalised tonic-clonic
seizures without focal onset. In the trial including adults only 61%
of participants were male (57% males in the oxcarbazepine group
and 64% in the phenytoin group) (Bill 1997). In the trial in-
cluding children and adolescents (Guerreiro 1997), 50% of par-
ticipants were male (47% males in the oxcarbazepine group and
52% in the phenytoin group). To be included in the two trials
(Bill 1997; Guerreiro 1997), participants had to have a minimum
of two seizures, separated by at least 48 hours, in the six months
before entering the study. In both trials the baseline assessment
included a medical and seizure history, physical examination, lab-
oratory evaluations, ECG, EEG and an optional cranial computed
tomography (CT) scan to rule out any progressive neurological
disorder such as a brain tumour. In Bill 1997 and Guerreiro 1997,
seizures were classified according to the 1981 International Classi-
fication of seizure types (Commission 1981). The study by Guer-
reiro and colleagues also used the 1989 classification of epilepsies
and epileptic syndromes (Commission 1989).
During the eight-week titration period, treatment was started with
daily doses of:
1. 300 mg oxcarbazepine or 100 mg phenytoin and then
increased bi-weekly (every two weeks) based on clinical response
(for adults) (Bill 1997);
2. 150 mg oxcarbazepine or 50 mg phenytoin and then
increased gradually based on clinical response (for children and
adolescents) (Guerreiro 1997).
No fixed titration schedule was used except that after eight weeks
participants were to be on a tid (three times per day) regimen
of oxcarbazepine or phenytoin with daily doses of 450 to 2400
mg and 150 to 800 mg, respectively. The daily dose range and
tid regimen were to be continued during the subsequent 48-week
maintenance period. However, adjustment of the daily dose ac-
cording to clinical response was possible during this period. The
median daily dose actually taken (with lower and upper quartiles)
for oxcarbazepine was 900 mg (900 mg; 1200 mg) in Bill 1997,
and 600 mg (450 mg; 900 mg) in Guerreiro 1997. The median
daily dose (with lower and upper quartiles) for phenytoin was 300
mg (300 mg; 300 mg) in Bill 1997, and 200 mg (150 mg; 300
mg) in Guerreiro 1997.
Individual participant data were not available for the remaining
trial (Aikia 1992), a single-centre trial conducted in Finland which
recruited 37 adult participants with newly onset seizures (19 to
oxcarbazepine and 18 to phenytoin) and reported the characteris-
tics and results for the 29 participants completing the study. The
majority of participants had focal onset seizures (72%), 38% of
participants were male and the mean age of included participants
was approximately 33 years. The outcomes evaluated were neu-
ropsychological assessment and cognitive functioning in three ma-
jor areas (verbal learning and memory, sustained attention, sim-
ple psychomotor speed), and they were measured at baseline, six
months’ and 12 months’ follow-up. MANOVA (repeated mea-
sures analysis of variance) for these assessments showed no statis-
tically significant interaction between treatment group and time.
Excluded studies
We excluded one study from the review as it was not fully ran-
domised (Sabers 1995, see Characteristics of excluded studies).
Risk of bias in included studies
For further details, see Characteristics of included studies, Figure
2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
We judged two studies to be at low risk of selection bias (Bill 1997;
Guerreiro 1997). Randomisation numbers were sequentially as-
signed across centres within each country. A computer-generated
randomisation scheme was used to provide balanced blocks of par-
ticipant numbers for each of the two treatment groups within each
centre. A block size of six was used (Pohlmann 2005 [pers comm]).
The trial reports for two studies did not provide details on alloca-
tion concealment (Bill 1997; Guerreiro 1997), but the trial statis-
tician explained in personal correspondence that allocation con-
cealment was achieved as follows: sequentially numbered pack-
ages were prepared which were identical and contained identical
tablets; and recruiting clinicians were asked to allocate each partic-
ipant the package with the lowest number available at the centre
(Pohlmann 2005 [pers comm]). We deemed these trials to be at
low risk of selection bias.
Participantswere “randomly allocated” to treatment inAikia 1992,
however the trial report did not provide methods used to generate
a random sequence or to conceal allocation, therefore we judged
the study to be at unclear risk of selection bias.
Blinding
We judged all three studies to be at low risk of performance bias
anddetectionbias.Two studieswere double-blindedby using divis-
ible tablets with identical appearance (Bill 1997; Guerreiro 1997).
The third study was also double-blinded, however the method of
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achieving the double-blind was not provided in the trial report
(Aikia 1992).
Incomplete outcome data
We judged all three studies to be at high risk of attrition bias.
Analyses were not performed using an intention-to-treat approach
in Aikia 1992: 29 participants who completed 12 months of fol-
low-up were included in analyses; and eight participants who ex-
perienced inadequate seizure control, adverse events or were non-
compliant were withdrawn from the study and excluded from
analysis.
For the studies for which IPD were provided (Bill 1997; Guerreiro
1997), analyses for time to six-month remission, time to 12-month
remission and time to first seizure could not be performed using an
intention-to-treat approach as participants who failed treatment
in both studies were not followed up after the time of treatment
failure.
In Bill 1997 and Guerreiro 1997, the numbers for premature dis-
continuation in the titration period differed from the numbers re-
ported in the publications (49 participants - 25 on oxcarbazepine
and 24 on phenytoin - in Bill 1997; and 31 participants - 15 on
oxcarbazepine and 16 on phenytoin - in Guerreiro 1997).We cor-
responded with the trial statistician about these differences and
they proposed a possible explanation: it is likely that the raw pre-
mature discontinuation data (0 or 1) as collected in the clinical
record file (CRF) were provided for this Cochrane Review, but for
the time to premature discontinuation analyses in the publication,
a derived premature discontinuation variable based on the “time
under assessment” was created (Pohlmann 2005 [pers comm]). If
certain participants had empty records in the maintenance period,
the created variable will indicate a premature discontinuation at
the end of the titration period, although in the CRF they were
coded as discontinuing during the maintenance period. If this was
the case, it is possible that we find fewer participants who discon-
tinued during the titration period, compared to the publication.
(Note that the trial statistician who proposed this explanation was
not the original trial statistician and could only explain how they
handled data at the time of the trial (in the 1990s). The data used
for the publication were not accessible at the time of our query
(Pohlmann 2005 [pers comm]).
Selective reporting
We judged all three studies to be at low risk of reporting bias.
Protocols were not available for the three included studies (Aikia
1992; Bill 1997;Guerreiro 1997), however unpublished IPDwere
provided in order to calculate outcomes used in this review for
two studies (Bill 1997; Guerreiro 1997), and neuropsychological
and cognitive outcomes were well reported in Aikia 1992.
Other potential sources of bias
We detected no other sources of bias in any of the three studies.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: oxcarbazepine versus phenytoin (primary outcomes);
Summary of findings 2 Summary of findings: oxcarbazepine
versus phenytoin (secondary outcomes)
Details regarding the number of participants contributing to each
analysis are given in Table 3. One participant in Bill 1997, and
three in Guerreiro 1997, had missing data for the main seizure
type at baseline and therefore their epilepsy type could not be de-
rived.We excluded these four participants from subgroup analyses
according to epilepsy types.
See Summary of findings for the main comparison for a summary
of the results for the primary outcome ’time to treatment failure
(for any reason related to treatment)’ and ’time to treatment failure
due to adverse events’ (stratified by epilepsy type), and Summary
of findings 2 for a summary of results for the secondary outcomes
’time to first seizure’ and ’time to 12-month remission’. Survival
curve plots are shown in Figure 4; Figure 5; Figure 6; Figure 7;
Figure 8; Figure 9; Figure 10; Figure 11; Figure 12; and Figure 13.
All survival curve plots were produced in Stata software version 14
(Stata 2015) using data from all trials providing IPD combined.
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Figure 4. Time to treatment failure (for any reason related to treatment) PHT= phenytoin;
OXC=oxcarbazepine
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Figure 5. Time to treatment failure due to adverse events PHT= phenytoin; OXC=oxcarbazepine. Y-axis of
the figure scaled down to a maximum of 0.3 as a small number of individuals failed treatment due to adverse
events
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Figure 6. Time to treatment failure due to lack of efficacy PHT= phenytoin; OXC=oxcarbazepine. Y-axis of
the figure scaled down to a maximum of 0.1 as a small number of individuals failed treatment due to lack of
efficacy and censoring marks removed to allow steps (events) on the curve to be seen.
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Figure 7. Time to treatment failure (for any reason related to treatment) - by epilepsy type PHT =
phenytoin; OXC = oxcarbazepine
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Figure 8. Time to first seizure post-randomisation PHT = phenytoin; OXC = oxcarbazepine
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Figure 9. Time to first seizure post-randomisation - by epilepsy type PHT = phenytoin; OXC =
oxcarbazepine
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Figure 10. Time to 12-month remission PHT = phenytoin; OXC = oxcarbazepine
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Figure 11. Time to 12-month remission - by epilepsy type PHT = phenytoin; OXC = oxcarbazepine
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Figure 12. Time to six-month remission PHT = phenytoin; OXC = oxcarbazepine
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Figure 13. Time to six-month remission - by epilepsy type PHT= phenytoin; OXC=oxcarbazepine
We note that participants with event times of zero (i.e. those who
experienced treatment failure or experienced seizure recurrence on
the day of randomisation) are not included in the ’Numbers at
risk’ on the graphs and that data are not stratified by trial within
these survival curve plots. All figures are intended to provide a
visual representation of outcomes, extent of follow-up and visual
differences between seizure types. These graphs are not intended to
show statistical significance and numerical values may vary com-
pared to the text due to differences in methodology.
We calculated all hazard ratios (HRs) presented below by generic
inverse variance fixed-effect meta-analysis unless otherwise stated.
All analyses met the assumption of proportional hazards (the ad-
dition of a time-varying covariate into the model was non-signif-
icant).
Primary outcome
Time to treatment failure (retention time)
For this outcome, a HR of less than one indicates a clinical advan-
tage for oxcarbazepine.
Times to treatment failure and reasons for treatment failure were
available for all 480 participants from the two trials providing IPD
(100% of IPD available). See Table 1 for reasons for premature
discontinuation of treatment (treatment failure) by treatment and
how we classified these reasons in analysis.
In Bill 1997, of the 287 participants who were randomised (143 to
oxcarbazepine and 144 to phenytoin), 117 participants discontin-
ued prematurely from the trial (40.4%); 56 (39.2%) in the oxcar-
bazepine group and 61 (42.2%) in the phenytoin group. Of these
participants, 28 (12 on oxcarbazepine and 16 on phenytoin) dis-
continued during the eight-week titration period. An additional
89 participants (44 on oxcarbazepine and 45 on phenytoin) dis-
continued during the 48-week maintenance period.
In Guerreiro 1997, of the 193 participants who were randomised
(97 to oxcarbazepine and 96 to phenytoin), 58 participants dis-
continued prematurely from the trial (30.1%); 24 (24.7%) in the
oxcarbazepine group and 34 (35.4%) in the phenytoin group. Of
these participants, 14 (6 on oxcarbazepine and 8 on phenytoin)
discontinuedduring the eight-week titrationperiod. An additional
44 participants (18 on oxcarbazepine and 26 on phenytoin) dis-
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continued during the 48-week maintenance period.
Therefore in total, 175 participants prematurely withdrew from
treatment (36.5% of 480 participants): 80 out of 240 participants
randomised to oxcarbazepine (33.3%) and 95 out of 240 partici-
pants randomised to phenytoin (39.6%).
We deemed 113 participants (64.6% of 175 treatment failures) to
have withdrawn for reasons related to the study drug: 50 (62.5%)
on oxcarbazepine and 63 (66.3%) on phenytoin, and we classed
these reasons as ’events’ in analysis. The most common treatment-
related reasons for treatment failure were:
1. non-compliance with treatment (or protocol violation, or
both), which accounted for 65 withdrawals (37.1% of total
treatment failures), 38 (47.5% of total treatment failures) on
oxcarbazepine and 27 (28.4% of total treatment failures) on
phenytoin; and
2. adverse events: 39 withdrawals (22.3% of total treatment
failures), 7 (8.8% of total treatment failures) on oxcarbazepine
and 32 (33.7% of total treatment failures) on phenytoin.
Only nine participants (1.8%) across the two trials withdrew due
lack of efficacy (i.e. continued seizures).
We classed the other 62 reasons (30 on oxcarbazepine and 32 on
phenytoin), whichweremostly losses to follow-up (53 participants
lost to follow-up, 11% of other withdrawals), to be not related to
the treatment and we censored these participants in the analysis,
in addition to the 305 participants (160 on oxcarbazepine and 145
on phenytoin) who completed the trial without withdrawing or
failing treatment.
Time to treatment failure for any treatment related reason
The overall pooledHR for this outcome (for 480 participants pro-
viding IPD from two trials) was 0.77 (95% confidence interval
(CI) 0.53 to 1.12, P=0.17, high-quality evidence; Analysis 1.1),
indicating a potential advantage with oxcarbazepine (i.e. treat-
ment failure may occur later with oxcarbazepine than phenytoin)
which is not statistically significant. No important heterogeneity
was present between trials (I² = 4%).
Time to treatment failure due to adverse events
Considering time to treatment failure due to adverse events (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooled HR (for 480 participants
providing IPD from two trials) was 0.22 (95% CI 0.10 to 0.51,
P = 0.0004, high-quality evidence, Analysis 1.2), indicating a sta-
tistically significant advantage with oxcarbazepine (i.e. treatment
failure due to adverse events occurs significantly later with oxcar-
bazepine than phenytoin). No heterogeneity was present between
trials (I²= 0%).
Time to treatment failure due to lack of efficacy
Considering time to treatment failure due to lack of efficacy (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooledHR (for 480 participants pro-
viding IPD from two trials) was 1.17 (95% CI 0.31 to 4.35, P =
0.82, moderate-quality evidence, Analysis 1.3). As the pooled HR
is quite imprecise, it is unclear whether there is an advantage to
either drug, or no difference between drugs. No heterogeneity was
present between trials (I² = 0%) and we note that the confidence
intervals of this pooled HR are very wide because of the small
number of participants across the two trials failing treatment due
to lack of efficacy, and therefore a small number of events within
the analysis (see Table 1).
Subgroup analyses: seizure type (focal versus generalised
onset)
For four participants, information on the type of seizures was not
available (one participant in Bill 1997, and three in Guerreiro
1997); we could not classify their epilepsy type and so we did not
include these participants in the subgroup analyses.
Considering time to treatment failure for any reason related to the
treatment, the overall pooled HR (adjusted by epilepsy type for
476 participants from two trials) was 0.78 (95% CI 0.53 to 1.14,
P = 0.20, moderate-quality evidence, see Analysis 1.4). This result
is similar to the unadjusted pooled HR (Analysis 1.1) and conclu-
sions remain unchanged following the exclusion of four individu-
als with missing epilepsy type. Again, no important heterogeneity
was present between trials (I² = 10%).
For individuals with focal onset seizures (333 participants from
two trials), the pooled HR was 0.69 (95% CI 0.43 to 1.09, P =
0.11, moderate-quality evidence, Analysis 1.4), indicating a po-
tential advantage with oxcarbazepine which is not statistically sig-
nificant. Amoderate amount of heterogeneity was present between
the two studies for individuals with focal onset seizures (I² = 35%)
and when we repeated the analysis using a random-effects model,
the numerical results were relatively similar and the results un-
changed (pooled HR 0.67, 95% CI 0.37 to 1.20; P = 0.17). For
individuals with generalised onset seizures (143 participants from
two trials), the pooled HR was 1.03 (95% CI 0.51 to 2.08, P =
0.93, low-quality evidence, Analysis 1.4). There are wide confi-
dence intervals around the pooledHRso it is unclearwhether there
is an advantage to either drug, or no difference between drugs. No
heterogeneity was present between trials (I² = 0%).
There was no statistically significant evidence of an interaction
between epilepsy type (focal onset versus generalised onset) and
treatment effect (test of subgroup differences: P = 0.34; I² statistic
for variability due to subgroup differences = 0%, Analysis 1.4).
We were unable to perform subgroup analysis for ’time to treat-
ment failure due to adverse events’ and ’time to treatment failure
due to lack of efficacy’ due to small numbers of participants with
each epilepsy type failing treatment for these reasons (see Table 1).
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Sensitivity analysis: only data from the double-blind period
of 392 days
Five participants had a recorded time of treatment failure greater
than 392 days (four in Bill 1997, and one in Guerreiro 1997); two
with generalised onset seizures and three with focal onset seizures.
When values greater than 392 days were censored in the analyses
(adjusted for epilepsy type), the numerical results were very similar
to the uncensored analyses and conclusions were unchanged (see
Table 4).
Sensitivity analysis: reclassification of epilepsy type
In the sensitivity analyses to investigatemisclassificationof epilepsy
type, we reclassified the 30 participants aged 30 or older with new
onset generalised seizures from one study (Bill 1997), to focal on-
set seizures or an uncertain seizure type. Overall the numerical
results (adjusted by epilepsy type) were quite similar, but substan-
tially more heterogeneity was present between the studies in both
analyses compared to the original analysis (Analysis 1.4) and some
numerical results within the subgroups by epilepsy type are quite
different (see Table 4).
Following reclassification, for the smaller subgroup of individuals
with generalised onset seizures and age of onset of 30 years or less
(113 participants from two trials), the pooled HR was 0.67 (95%
CI 0.31 to 1.46; P = 0.32; I²= 58%, see Table 4, Analysis 1.5 and
Analysis 1.6), indicating a potential advantage with oxcarbazepine
which is not statistically significant.Whenwe repeated the analysis
using a random-effects model, the pooled HR was 0.85 (95% CI
0.21 to 3.46; P = 0.82), indicating no clear advantage to either
drug (Analysis 1.5).
For the larger subgroup of individuals with focal onset seizures
(including the 30 participants aged 30 or older with new onset
generalised seizures, a total of 363 participants from two trials),
the pooled HR was 0.80 (0.52 to 1.24; P = 0.32; I²= 66%, see
Table 4 and Analysis 1.5), indicating a potential advantage with
oxcarbazepine which is not statistically significant. When we re-
peated the analysis using a random-effects model, the pooled HR
was 0.74 (95% CI 0.34 to 1.61; P = 0.44), so conclusions were
unchanged.
For the 30 participants aged 30 or older with new onset generalised
seizures, the HR is quite imprecise so it is unclear whether there
is an advantage to either drug, or no difference between drugs
(6.23, 95% CI 0.73 to 53.44, P = 0.09; see Table 4 and Analysis
1.6). As in the original analysis, there was also no statistically
significant evidence of an interaction between epilepsy type (focal
onset versus generalised onset) and treatment effect in either of the
sensitivity analyses (see Table 4, Analysis 1.5 and Analysis 1.6 for P
values of test for subgroup differences). However, in the sensitivity
analysis reclassifying to uncertain seizure type, the I² statistic for
variability due to subgroup differences increased from 0% to I² =
49.2%, suggesting some potential differences in treatment effect
by epilepsy type following reclassification of epilepsy type.
We were unable to perform sensitivity analyses for ’time to treat-
ment failure due to adverse events’ and ’time to treatment failure
due to lack of efficacy’ due to small numbers of participants with
each epilepsy type failing treatment for this reason (see Table 1).
Secondary outcomes
Time to first seizure post-randomisation
For this outcome, a HR of less than one indicates a clinical advan-
tage for oxcarbazepine.
Data for 472 participants (98.3% of those providing IPD) from
two trials were available for the analysis of this outcome. This
outcome could not be calculated for eight participants (five from
Bill 1997, and three from Guerreiro 1997), due to missing data
(no data for mean frequency of seizures in the maintenance period
as well as the titration period; number of days on trial medica-
tion ranged between one and 36 days for these eight participants).
Analyses could not be performed with an intention-to-treat ap-
proach as participants who withdrew from both studies were not
followed up after time of treatment failure.
The overall pooled HR (for 472 participants providing IPD from
two trials) was 0.93 (95% CI 0.72 to 1.21, P = 0.60, moderate-
quality evidence, Analysis 1.7), indicating no clear advantage of
either drug. Noheterogeneity was present between trials (I² = 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
For four participants, information on the type of seizures was not
available (one participant in Bill 1997, and three in Guerreiro
1997); we could not classify their epilepsy type and so we did not
include these participants in the subgroup analyses.
The overall pooled HR (adjusted by epilepsy type for 468 partic-
ipants from two trials) was 0.97 (95% CI 0.75 to 1.26, P = 0.81,
moderate-quality evidence, see Analysis 1.8). This result is similar
to the unadjusted pooled HR (Analysis 1.7) and conclusions re-
main unchanged following the exclusion of four individuals with
missing epilepsy type. No heterogeneity was present between trials
(I² = 0%).
For individuals with focal onset seizures (326 participants from
two trials), the pooled HR was 0.92 (95% CI 0.68 to 1.25, P =
0.61, moderate-quality evidence, Analysis 1.8), indicating no clear
advantage of either drug. No heterogeneity was present between
trials (I² = 0%). For individuals with generalised onset seizures
(142 participants from two trials), the pooled HR was 1.11 (95%
CI 0.66 to 1.86, P = 0.69, low-quality evidence, Analysis 1.8),
indicating no clear advantage for either drug. No heterogeneity
was present between trials (I² = 0%).
There was no statistically significant evidence of an interaction
between epilepsy type (focal onset versus generalised onset) and
treatment effect (test of subgroup differences: P = 0.55, I² statistic
for variability due to subgroup differences = 0% (Analysis 1.8).
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Sensitivity analysis: only data from the double-blind period
of 392 days
No participants had a time of first seizure greater than 392 days
into the follow-up time, therefore results were identical for the
analysis of the full follow-up and for the double-blind period only
(see Table 4).
Sensitivity analysis: reclassification of epilepsy type
In the sensitivity analyses to investigatemisclassificationof epilepsy
type, we reclassified the 29 participants aged 30 or older with new
onset generalised seizures fromone study (Bill 1997), to focal onset
seizures or an uncertain seizure type. The numerical results overall
and for individuals with focal onset seizures were similar to the
original analyses and conclusions were unchanged.
Following reclassification, for the smaller group of individuals with
generalised onset seizures (113 participants from two trials), the
pooled HR was 1.44, 95% CI 0.79 to 2.62, P = 0.23, I² = 0%,
suggesting a potential advantage with phenytoin (i.e. first seizure
recurrence may occur later on phenytoin than oxcarbazepine), but
this potential advantage is quite imprecise so an advantage with
oxcarbazepine, or no difference between drugs, cannot be ruled
out. Also for the 29 participants aged 30 or older with new onset
generalised seizures, the HR is quite imprecise so it is unclear
whether there is an advantage to either drug, or no difference
between drugs (0.38, 95% CI 0.10 to 1.44, P = 0.16) (see Table
4).
Within the original analysis, there was no evidence of an inter-
action between epilepsy type (focal onset versus generalised on-
set) and treatment effect (see Analysis 1.8). However, within the
two sensitivity analyses, while there was no statistically significant
evidence of an interaction, the I² statistics for variability due to
subgroup differences were relatively high (I² = 54% and 45.5%
respectively), suggesting some potential differences in treatment
effect by epilepsy type following reclassification of epilepsy type
(see Table 4).
Time to achieve 12-month remission
For this outcome, a HR of less than one indicates a clinical advan-
tage for phenytoin.
Data for 472 participants (98.3% of those providing IPD) from
two trials were available for the analysis of this outcome. We could
not calculate this outcome for eight participants (five from Bill
1997, and three fromGuerreiro1997) due tomissing data (no data
for mean frequency of seizures in the maintenance period as well
as the titration period; number of days on trial medication ranged
between one and 36 days for these eight participants). Analyses
could not be performed with an intention-to-treat approach as
participants who withdrew from both studies were not followed
up after time of treatment failure.
The overall pooled HR (for 472 participants providing IPD from
two trials) was 1.09 (95% CI 0.80 to 1.47, P = 0.58, moderate-
quality evidence, Analysis 1.9), indicating no clear advantage of
either drug. Noheterogeneity was present between trials (I² = 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
For four participants, information on the type of seizures was not
available (one participant in Bill 1997, and three in Guerreiro
1997); we therefore could not classify their epilepsy type and so
we did not include these participants in the subgroup analyses.
The overall pooled HR (adjusted by epilepsy type for 468 partic-
ipants from two trials) was 1.04 (95% CI 0.77 to 1.41, P = 0.81,
moderate-quality evidence, see Analysis 1.10). This result is sim-
ilar to the unadjusted pooled HR (Analysis 1.9) and conclusions
remain unchanged following the exclusion of four individuals with
missing epilepsy type. No heterogeneity was present between trials
(I² = 0%).
For individuals with focal onset seizures (326 participants from
two trials), the pooled HR was 1.09 (95% CI 0.75 to 1.57, P
= 0.66, moderate-quality evidence, Analysis 1.10), indicating no
clear advantage of either drug. No heterogeneity was present be-
tween trials (I² = 0%). For individuals with generalised onset
seizures (142participants from two trials), the pooledHRwas 0.94
(95% CI 0.55 to 1.62, P = 0.83, low-quality evidence, Analysis
1.10), indicating no clear advantage of either drug. No hetero-
geneity was present between trials (I² = 0%).
There was no statistically significant evidence of an interaction
between epilepsy type (focal onset versus generalised onset) and
treatment effect (test of subgroup differences: P = 0.67, I² statistic
for variability due to subgroup differences = 0% (Analysis 1.10).
Sensitivity analysis: only data from the double-blind period
of 392 days
Fifteen participants had a time to 12-month remission greater
than 392 days (nine participants in Bill 1997, and six in Guerreiro
1997); three with generalised onset seizures and 12 with focal on-
set seizures. When we censored values greater than 392 days in
analyses (adjusted for epilepsy type), numerical results overall and
for individuals with generalised onset seizures were very similar to
the original analyses and conclusions were unchanged. For indi-
viduals with focal onset seizures there was a slight, but not statisti-
cally significant, potential advantage with oxcarbazepine (i.e. 12-
month remission may occur earlier on oxcarbazepine than pheny-
toin), compared to the original analysis which showed no clear
advantage to either drug (see Table 4).
Sensitivity analysis: reclassification of epilepsy type
In the sensitivity analyses to investigatemisclassificationof epilepsy
type, we reclassified the 29 participants aged 30 or older with new
onset generalised seizures fromone study (Bill 1997), to focal onset
seizures or an uncertain seizure type. The numerical results overall
and for individuals with focal onset seizures were similar to the
original analyses and conclusions were unchanged.
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Following reclassification, for the smaller group of individuals with
generalised onset seizures (113 participants from two trials), the
pooled HR was 0.75, 95% CI 0.40 to 1.41, P = 0.37, I² = 0%,
suggesting a potential advantage with phenytoin (i.e. 12-month
remission may occur earlier with phenytoin than oxcarbazepine).
For the 29 participants aged 30 or older with new onset generalised
seizures, the HR is quite imprecise so it is unclear whether there
is an advantage to either drug, or no difference between drugs
(2.05, 95% CI 0.68 to 6.17, P = 0.20) (see Table 4). As in the
original analysis, there is also no statistically significant evidence of
an interaction between epilepsy type (focal onset versus generalised
onset) and treatment effect (see Table 4).
Time to achieve six-month remission
For this outcome, a HR less than one indicates a clinical advantage
for phenytoin.
Data for 472 participants (98.3% of those providing IPD) from
two trials were available for the analysis of this outcome. We could
not calculate this outcome for eight participants (five from Bill
1997, and three fromGuerreiro1997) due tomissing data (no data
for mean frequency of seizures in the maintenance period as well
as the titration period; number of days on trial medication ranged
between one and 36 days for these eight participants). Analyses
could not be performed with an intention-to-treat approach as
participants who withdrew from both studies were not followed
up after time of treatment failure.
The overall pooled HR (for 472 participants providing IPD from
two trials) was 1.12 (95% CI 0.87 to 1.43, P = 0.38, moderate-
quality evidence, Analysis 1.12), indicating no clear advantage to
either drug. Noheterogeneity was present between trials (I² = 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
For four participants, information on the type of seizures was not
available (one participant in Bill 1997, and three in Guerreiro
1997); therefore we could not classify their epilepsy type and so
we did not include these participants in the subgroup analyses.
The overall pooled HR (adjusted by epilepsy type for 468 partic-
ipants from two trials) was 1.06 (95% CI 0.82 to 1.36, P = 0.65,
moderate-quality evidence, see Analysis 1.12). This result is simi-
lar to the unadjusted pooled HR (Analysis 1.11) and conclusions
remain unchanged following the exclusion of four individuals with
missing epilepsy type. No heterogeneity was present between trials
(I² = 0%).
For individuals with focal onset seizures (326 participants from
two trials), the pooled HR was 1.17 (95% CI 0.87 to 1.58, P
= 0.29, moderate-quality evidence, Analysis 1.12), suggesting a
slight potential advantage with oxcarbazepine (i.e. that six-month
remission may occur earlier on oxcarbazepine than phenytoin)
which is not statistically significant. No heterogeneity was present
between trials (I² = 0%). For individuals with generalised onset
seizures (142participants from two trials), the pooledHRwas 0.83
(95% CI 0.53 to 1.31, P = 0.43, low-quality evidence, Analysis
1.12), suggesting a slight potential advantage with phenytoin. No
heterogeneity was present between trials (I²= 0%).
There was no statistically significant evidence of an interaction
between epilepsy type (focal onset versus generalised onset) and
treatment effect (test of subgroup differences: P = 0.21, I² statistic
for variability due to subgroupdifferences = 35.8%,Analysis 1.12).
Sensitivity analysis: only data from the double-blind period
of 392 days
No participants achieved six-month remission after 392 days into
the follow-up time, therefore results were identical for the analysis
of the full follow-up and for the double-blind period only (see
Table 4).
Sensitivity analysis: reclassification of epilepsy type
In the sensitivity analyses to investigatemisclassificationof epilepsy
type, we reclassified the 29 participants aged 30 or older with new
onset generalised seizures fromone study (Bill 1997), to focal onset
seizures or an uncertain seizure type. Numerical results overall and
for individuals with focal onset seizures were similar to the original
analyses and conclusions were unchanged.
Following reclassification, the smaller group of individuals with
generalised onset seizures (113 participants from two trials), the
pooled HR was 0.72, 95% CI 0.43 to 1.23, P = 0.23, I² = 0%,
suggesting a potential advantage with phenytoin (i.e. six-month
remission may occur earlier with phenytoin than oxcarbazepine).
For the 29 participants aged 30 or older with new onset generalised
seizures, the HR is quite imprecise so it is unclear whether there is
an advantage to either drug, or no difference between drugs (1.51,
95% CI 0.59 to 3.86, P = 0.40) (see Table 4).
Within the original analysis, there was no statistically significant
evidence of an interaction between epilepsy type (focal onset ver-
sus generalised onset) and treatment effect (see Analysis 1.12)
and within the sensitivity analysis of reclassification to uncertain
seizure type (test of subgroup differences: P = 0.22, I² statistic
for variability due to subgroup differences = 33.2%, see Table 4).
However, within the sensitivity analysis of reclassification to focal
onset seizures, while there was no statistically significant evidence
of an interaction (P = 0.10), the I² statistics for variability due to
subgroup differences were relatively high in the sensitivity analyses
(I² = 62.4%), suggesting some potential differences in treatment
effect by epilepsy type following reclassification of epilepsy type
(see Table 4).
Incidence of adverse events
See Table 5 for details of all adverse event data provided in the
studies included in this review. We note that adverse event in-
formation was not included in IPD requests conducted for the
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original version of this review, therefore we extracted information
on adverse events from the published reports of two studies (Bill
1997; Guerreiro 1997). No adverse event information was pro-
vided in Aikia 1992.
Overall, most adverse events were reported in more participants
taking phenytoin than those taking oxcarbazepine (although we
did not compare the rates of adverse events by drug statistically).
The most common adverse events reported in more than 10% of
participants on either drug were as follows.
1. Somnolence: reported by 134 participants on both drugs
(28% of total participants), with similar rates across the two
drugs.
2. Headache: reported by 74 participants on both drugs (15%
of total participants), with similar rates across the two drugs.
3. Dizziness: reported by 70 participants on both drugs
(14.5% of total participants), reported by slightly more
participants on phenytoin (18%) than oxcarbazepine (11%).
4. Gum hyperplasia: reported by 46 participants on both
drugs (9.5% of total participants), reported by substantially
more participants on phenytoin (18%) than oxcarbazepine (2%).
Additional specific adverse events reported in less than 5% of total
participants (which were reported by slightly more participants
on phenytoin than oxcarbazepine) were: tremor, ataxia, diplopia,
hypertrichosis and vomiting. Slightly more participants reported
acne on oxcarbazepine than phenytoin.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oxcarbazepine compared with phenytoin for epilepsy
Patient or population: adults and children with newly diagnosed epilepsy
Settings: outpat ients
Intervention: oxcarbazepine
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Oxcarbazepine
Time to first seizure
(post- randomisation)
All participants
Range of follow-up: 1 to
779 days
The median t ime to f irst
seizure was 230 days in
the phenytoin group
The median t ime to f irst
seizure was 252 days
(22 days longer) in the
oxcarbazepine group
HR 0.97
(0.75 to 1.26)a
468
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
Time to first seizure
(post- randomisation)
Subgroup: focal onset
seizures
Range of follow-up: 1 to
498 days
The median t ime to
treatment f irst seizure
was 224 days in the
phenytoin group
The median t ime to f irst
seizure was 233 days
(9 days longer) in the
oxcarbazepine group
HR 0.92
(0.68 to 1.25)
326
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
Time to first seizure
(post- randomisation)
Subgroup: generalised on-
set seizures
Range of follow-up: 1 to
779 days
The 25th percent ile* *
of t ime to f irst seizure
was 78 days in the
phenytoin group
The 25th percent ile* *
of t ime to f irst seizure
was 28 days (50 days
shorter) in the oxcar-
bazepine group
HR 1.11
(0.66 to 1.86)
142
(2 trials)
⊕⊕©©
lowb,c
HR < 1 indicates a clin-
ical advantage for ox-
carbazepine
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Time to achieve 12-
month remission
(seizure- free period)
All participants
Range of follow-up: 1 to
532 days
The median t ime to 12-
month remission was
401 days in the pheny-
toin group
The median t ime to 12-
month remission was
365 days (36 days
shorter) in the oxcar-
bazepine group
HR 1.04
(0.77 to 1.41)a
468
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a
clinical advantage for
phenytoin
Time to achieve 12-
month remission
(seizure- free period)
Subgroup: focal onset
seizures
Range of follow-up: 1 to
532 days
The median t ime to 12-
month remission was
401 days in the pheny-
toin group
The median t ime to 12-
month remission was
390 days (11 days
shorter) in the oxcar-
bazepine group
HR 1.09
(0.75 to 1.57)
326
(2 trials)
⊕⊕⊕©
moderateb
HR < 1 indicates a
clinical advantage for
phenytoin
Time to achieve 12-
month remission
(seizure- free period)
Subgroup: generalised on-
set seizures
Range of follow-up: 1 to
532 days
The median t ime to 12-
month remission was
365 days in the pheny-
toin group
The median t ime to 12-
month remission was
365 days (0 days
shorter or longer) in the
oxcarbazepine group
HR 0.94
(0.55 to 1.62)
142
(2 trials)
⊕⊕©©
lowb,c
HR < 1 indicates a
clinical advantage for
phenytoin
* Illustrat ive risks in the oxcarbazepine and phenytoin groups are calculated at the median t ime to f irst seizure or t ime to 12-month remission (i.e. the t ime to 50% of
part icipants experiencing a f irst seizure or 12-months of remission) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime
to f irst seizure’ or ’t ime to 12-month remission’ between the treatment groups
* * The 25th percent ile of t ime to f irst seizure (i.e. the t ime to 25% of part icipants experiencing a f irst seizure) is presented for the subgroup with generalised seizures as less
than 50% of part icipants experienced a seizure recurrence in both groups, therefore the median t ime could not be calculated
Abbreviations: 95% CI: 95% conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a. Pooled hazard rat io for all part icipants adjusted for epilepsy type.3
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b. Downgraded once due to risk of bias: as part icipants who failed treatment or withdrew f rom the treatment were no longer
followed up in the study, remission and seizure outcomes had to be censored at t ime of treatment failure, therefore remission
and seizure outcomes could not be analysed with an intent ion-to-treat approach.
c. Downgraded once due to risk of bias: up to 29% of adult part icipants classif ied as experiencing generalised onset seizures
(in Bill 1997) may have had their epilepsy type wrongly classif ied, and sensit ivity analyses show that m isclassif icat ion may
have had an impact on the conclusions drawn for individuals with generalised seizures and whether an interact ion between
treatment ef fect and epilepsy type exists.
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D I S C U S S I O N
Summary of main results
In this review we included individual participant data (IPD) from
480 out of 517 participants (93%), from two out of three trials
in which participants were randomised to either oxcarbazepine or
phenytoin.
Analyses of all participants (without adjustment for epilepsy type)
indicated that treatment failure due to adverse events occurs sig-
nificantly later with oxcarbazepine than phenytoin (pooled hazard
ratio (HR) 0.22, 95% confidence interval (CI) 0.10 to 0.51, P =
0.0004, high-quality evidence). The analyses also showed no clear
difference between the drugs in terms of time to treatment failure
due to lack of efficacy (pooled HR 1.17, 95% CI 0.31 to 4.35, P
= 0.82, moderate-quality evidence), although relatively few par-
ticipants withdrew from the two trials due to lack of efficacy.
Moderate-quality evidence from analyses with and without adjust-
ment for epilepsy type, as well as sensitivity analysis, suggested a
potential clinical advantage with oxcarbazepine in terms of time
to treatment failure for any reason related to treatment, though
this effect was not statistically significant (pooled HR 0.78 (95%
CI 0.53 to 1.14, P = 0.20). This non-significant clinical advan-
tage was also consistently observed for individuals with focal onset
seizures (pooled HR 0.69, 95% CI 0.43 to 1.09, P = 0.11, mod-
erate-quality evidence), but results were more imprecise and less
consistent following sensitivity analysis for individuals with gen-
eralised onset seizures (pooledHR 1.03 (95% CI 0.51 to 2.08, P =
0.93, low-quality evidence). Substantial heterogeneity was intro-
duced into analysis following reclassification of individuals aged
30 or older with new onset generalised seizures, and therefore it
is difficult to make a conclusion regarding the comparative time
to treatment failure of the two treatments due to variability and
potential confounding from seizure misclassification.
The results of this review provide moderate- to low-quality evi-
dence for secondary efficacy outcomes (time to first seizure post-
randomisation and time to six- and 12-month remission from
seizures). No statistically significant differences were found overall
or by epilepsy-type subgroups, and no clear differences between
drugs were observed overall. There are consistent trends in all of
the analyses (including sensitivity analyses) indicating a poten-
tial advantage with oxcarbazepine for participants with focal onset
seizures (i.e. first seizure recurrence may occur later and seizure re-
mission may occur earlier on oxcarbazepine than phenytoin), but
results are less consistent and more imprecise for individuals with
generalised onset seizures, and the results for this epilepsy-type
subgroup may have been confounded by seizure misclassification.
In most cases, adverse events were reported in more participants
on phenytoin than participants on oxcarbazepine (although we
did not compare the rates of adverse events by drug statistically).
The most common adverse events reported in more than 10%
of participants on either drug were somnolence (28% of total
participants, with similar rates across the two drugs), headache
(15% of total participants, with similar rates across the two drugs),
dizziness (14.5% of total participants, reported by slightly more
participants on phenytoin (18%) than oxcarbazepine (11%)) and
gum hyperplasia (reported by substantially more participants on
phenytoin (18%) than oxcarbazepine (2%)).
Overall completeness and applicability of
evidence
We have gratefully received IPD for 480 out of 517 participants
(93%) from two trials (Bill 1997; Guerreiro 1997), but we were
not able to make contact with the authors of a third eligible trial of
37 participants (Aikia 1992), and no relevant data were published
within the trial report to include within the analyses of this review.
Both trials included in IPD meta-analysis used adequate meth-
ods of randomisation and adequate methods of allocation conceal-
ment, both were double-blinded and attrition rates (loss to follow-
up and exclusions) were similar in the oxcarbazepine and pheny-
toin groups, with slightly more participants failing or withdrawing
from treatment in the phenytoin group compared to the oxcar-
bazepine group in both trials (see Table 1). The main difference
between the trials is that one recruited adults whilst the other re-
cruited children, which is a potential source of heterogeneity. The
majority of participants (333, 70%) had focal onset seizures while
143 (30%) were classified as having generalised onset seizures. The
follow-up period in both trials was less than two years, which is
relatively short given that epilepsy is a chronic condition often re-
quiring many years of treatment. Other reviews within this series
of pairwise IPD monotherapy reviews have included studies with
over 10 years of follow-up (Marson 2000; Nevitt 2017b; Nevitt
2018a; Nevitt 2018b; Nolan 2013c; Nevitt 2018c; Nolan 2016b).
A major methodological issue in both of the trials is that partici-
pants were no longer followed up after the allocated treatment was
withdrawn, and hence had to be censored at the time of treatment
failure for the analyses of seizure and remission outcomes. This
failure to follow participants up after the failure or withdrawal of
allocated treatment violates the principle of intention-to-treat and
may bias the seizure and remission analyses, as treatment may have
been withdrawn for differing reasons which may have lead to in-
formative censoring. For these reasons the analyses of seizure and
remission outcomes require cautious interpretation, although no
statistically significant differences between treatments or between
epilepsy types were found in any case.
Quality of the evidence
The two trials with IPD available for this review were generally
of good quality (Bill 1997; Guerreiro 1997), however, both trials
were at high risk of attrition bias because individuals who failed
treatment were not followed up in terms of seizures and remis-
sion outcomes (see Incomplete outcome data (attrition bias) and
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Overall completeness and applicability of evidence). Furthermore,
for Bill 1997, there was evidence that up to 29% of adult partici-
pants classified as experiencing generalised onset seizures may have
had their epilepsy type wrongly classified; and sensitivity analyses
show thatmisclassification may have had an impact on the conclu-
sions drawn for individuals with generalised seizures and whether
an interaction between treatment effect and epilepsy type exists.
The trial for which IPD was not provided was generally unclear
regarding methodology employed for randomisation, allocation
concealment and blinding and was also of high risk of attrition
bias (Aikia 1992).
Overall, due to the documented methodological issues that may
have introduced heterogeneity, biases and imprecision into our
meta-analyses, we rated the evidence provided in this review
as moderate to low quality according to GRADE criteria (See
Summary of findings for the main comparison and Summary of
findings 2). The limited evidence in this review is insufficient for
this review alone to inform clinical decisions to use one drug over
the other.
Potential biases in the review process
We were able to include IPD for 480 out of 517 participants
(93%) from two out of three trials included in this review, and con-
ducted all analyses as IPD analyses. Such an approach has many
advantages, such as enabling the standardisation of definitions of
outcomes across trials. Attrition and reporting biases can also be
reduced as additional analyses can be performed and additional
outcomes calculated from unpublished data. For the outcomes we
used in this review that are of a time-to-event nature, an IPD ap-
proach is considered to be the ’gold standard’ approach to analysis
(Parmar 1998).
However, despite the advantages of this approach, for reasons out
of our control we were not able to obtain IPD for 37 participants
from one eligible trial and no aggregate data were available for our
outcomes of interest in study publications; therefore, we had to
exclude 7% of eligible participants from our analyses, which may
have introduced bias to the review. However, given the relatively
small amount of data excluded, and that no differences were found
between treatments in terms of the outcomes measures in Aikia
1992, we do not believe that our conclusions would have changed
had the IPD for this trial been available.
Finally, we made some assumptions in the statistical methodol-
ogy used in this review. We received information regarding the
mean number of seizures per week in the titration (eight weeks)
and maintenance phases (48 weeks) for both trials but we did not
receive precise dates of seizures. Using these data, we were able
to interpolate the dates of seizures assuming a uniform distribu-
tion so that we could calculate the outcomes time to first seizure
and time to six- and 12-month remission. We are aware that an
individual’s seizure patterns may be non-linear; therefore, we rec-
ommend caution when interpreting the numerical results of the
seizure-related outcomes.
Agreements and disagreements with other
studies or reviews
To our knowledge, together with previous versions of this review,
this is the only systematic review and meta-analysis that compares
oxcarbazepine and phenytoinmonotherapy for focal onset seizures
and generalised onset tonic-clonic seizures. A network meta-anal-
ysis has been published (Nevitt 2017a), which compares all di-
rect and indirect evidence on oxcarbazepine, phenytoin, and other
standard and new antiepileptic drugs licensed for monotherapy.
The results of this review generally agree with the results of the net-
work meta-analysis; results of the network meta-analysis showed
no statistically significant differences between oxcarbazepine and
phenytoin for any of the outcomes considered (treatment failure,
seizure recurrence and seizure remission).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current UK guidelines recommend carbamazepine or lamotrigine
as first-line treatment for adults and children with new onset focal
seizures and sodium valproate for adults and children with new
onset generalised seizures (NICE 2012).
Evidence provided by this review for individuals with generalised
onset seizures is of moderate to low quality and does not inform
current treatment policy. For all individuals regardless of epilepsy
type, high-quality evidence provided by this review indicates that
treatment failure due to adverse events occurs significantly later
on oxcarbazepine than phenytoin. For individuals with focal onset
seizures, moderate-quality evidence provided by this review sug-
gests that oxcarbazepine may be superior to phenytoin in terms of
treatment failure for any reason, seizure recurrence and seizure re-
mission. Therefore, where first-line recommended treatments are
not suitable for an individual and where an alternative treatment
option is required, oxcarbazepine may be a preferable alternative
treatment than phenytoin, particularly for individuals with focal
onset seizures.
Implications for research
This review highlights the need for comparative antiepileptic drug
monotherapy trials that measure longer-term outcomes, as well as
the need to continue to follow participants up after randomised
treatment has been withdrawn in order to comply with the princi-
ple of intention-to-treat and to avoid the problems of informative
censoring. It is essential that the designs of future antiepileptic drug
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monotherapy trials aim to recruit individuals with specific epilepsy
syndromes, and that future trials are powered to detect a differ-
ence between particular antiepileptic drugs. An approach likely to
reflect and inform clinical practice, and be statistically powerful,
would be to recruit heterogeneous populations for whom epilepsy
syndromes have been adequately defined, with testing for inter-
action between treatment and epilepsy syndrome. In view of po-
tential problems of misclassification, syndromes need to be well
defined, with use of adequate checking mechanisms to ensure that
classifications are accurate, and a system to recognise uncertainty
surrounding epilepsy syndromes in individuals within trials.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-event
nature, require very careful consideration. While the majority of
trials of a monotherapy design record an outcome measuring effi-
cacy (seizure control) and an outcome measuring tolerability (ad-
verse events), there is little uniformity between the definition of
the outcomes and the reporting of the summary statistics related
to the outcomes (Nolan 2013b), which precludes the use of an ag-
gregate data approach to meta-analysis in reviews of monotherapy.
Where trial authors cannot or will not make individual participant
data available for analysis, we are left with no choice but to exclude
a proportion of relevant evidence from the review, which may im-
pact upon the interpretation of the results of the review and the
applicability of the evidence and conclusions. The International
League Against Epilepsy recommends that trials of a monotherapy
design should adopt a primary effectiveness outcome of time to
treatment failure (i.e. retention time) and should be of at least 48
weeks’ duration to allow for assessment of longer-term outcomes,
such as remission (ILAE 1998; ILAE 2006). If trials followed these
recommendations, an aggregate data approach to meta-analysis
may be feasible, which would reduce the resources and time re-
quired from an individual participant data approach.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aikia 1992
Methods Randomised, double-blinded, parallel-group study
Participants Adult participants with newly diagnosed epilepsy and “normal intellectual capacity” with
a minimum of 2 seizures in the last 2 years or 1 seizure and an epileptiform EEG
Number randomised: total = 37, OXC = 19, PHT = 18
Mean age of 29 included participants (SD): OXC = 33.6 (14) years, PHT = 32.7 (12.5)
years
11 out of 29 included participants male (38%), 21 out of 29 included participants with
focal epilepsy (72%); see Notes
Interventions Monotherapy with oxcarbazepine or phenytoin
4- to 8-week titration period until serum concentrations reached 30 µmol/litre to 120
µmol/litre for OXC and 40 µmol/litre to 80 µmol/litre for PHT, followed by a main-
tenance phase of 12 months
Outcomes Neuropsychological assessment and cognitive functioning in 3 major areas at baseline,
6 months and 12 months follow-up:
1. verbal learning and memory
2. sustained attention
3. simple psychomotor speed
Notes Participants experiencing inadequate seizure control, adverse events or those who were
non-compliant were withdrawn from the study and excluded from analysis (5 fromOXC
group and 3 from PHT group). Results are presented only for 29 participants (OXC =
14 and PHT = 15) completing the study
Outcomes for this review were not reported; IPD were not available (we could not make
contact with original trial authors to request IPD)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were “randomly assigned” to
treatment; no further information pro-
vided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “The study followed a double blind de-
sign”; no further information provided re-
garding how the double-blindwas achieved
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Aikia 1992 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat approach not taken: re-
sults reported only for 29 participants
(OXC= 14 and PHT = 15) who completed
12-month follow-up. Eight participants ex-
periencing inadequate seizure control, ad-
verse events or those who were non-com-
pliant (OXC = 5 and PHT = 3) were ex-
cluded from analysis and results
Selective reporting (reporting bias) Low risk No protocol available and outcomes cho-
sen for this review not reported Neuropsy-
chological and cognitive outcomes well re-
ported and treatment withdrawal rates re-
ported
Other bias Low risk No other sources of bias detected
Bill 1997
Methods Multicentre, double-blind, parallel-group trial conducted in centres in Argentina, Brazil,
Mexico, South Africa
Written informed consent obtained from participants or parents/guardians
Approved by local ethics committees
Conducted 1991 to first quarter of 1995
Participants Participants aged between 16 and 65 years with newly diagnosed epilepsy with focal
seizures or generalised tonic-clonic seizures
1 participant above the upper age limit (aged 91) included in efficacy and tolerability
analyses
A minimum of 2 seizures, separated by at least 48 hours, within 6 months preceding
trial entry
No previous AED, except emergency treatment of seizures for a maximum of 3 weeks
prior to trial entry
Number randomised: total = 287, OXC = 143, PHT = 144
174 male (61%); 182 focal epilepsy (63%)
Interventions Monotherapy with oxcarbazepine or phenytoin. Eight-week titration period started with
300 mg OXC or 100 mg PHT, increased bi-weekly, based on clinical response
After 8 weeks participants were to be on a tid regimen with daily doses of 450 mg to
2400 mg OXC or 150 mg to 800 mg PHT
Continued during 48-week maintenance with adjustment according to clinical response
A third long-term, open-label extension phase followed themaintenance period.Double-
blind results only are reported
Outcomes Efficacy: proportion of seizure-free participants who had at least 1 seizure assessment
during the maintenance period
Tolerability: comparison of participants who prematurely discontinued because of ad-
verse experiences
43Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bill 1997 (Continued)
Clinical utility: comparing premature discontinuation
Notes IPD provided for all outcomes of the review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment groups randomised in 1:1 ratio
across centres via computer-generated ran-
domisation numbers over balanced blocks
of size 6
Allocation concealment (selection bias) Low risk Allocation concealment was achieved with
sequentially numbered packages which
were identical and contained identical
tablets (informationprovided by trial statis-
tician)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Trial conducted in 2 phases: 56-week, dou-
ble-blind phase followed by long-term,
open-label extension
Double-blind phase results reported only
Blind achieved with divisible OXC and
PHT tablets identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates reported in both treat-
ment phases, participants withdrawing
from treatment were no longer followed
up so seizure outcomes had to be censored
at time of treatment failure and therefore
analyses for remission and seizure outcomes
could not adopt an ITT approach
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk No other sources of bias detected
Guerreiro 1997
Methods Multicentre, double-blind, parallel-group trial conducted in centres in Argentina and
Brazil
Written informed consent obtained from participants or parents/guardians
Approved by local ethics committees
Conducted 1991 to first quarter of 1995
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Guerreiro 1997 (Continued)
Participants Participants aged 5 to 18 years with newly diagnosed epilepsy with focal seizures or
generalised tonic clonic seizures
A minimum of 2 seizures, separated by at least 48 hours, within 6 months preceding
trial entry
No previous AED, except emergency treatment of seizures for a maximum of 3 weeks
prior to trial entry
Number randomised: total = 193, OXC = 97, PHT = 96
96 male (50%); 151 focal epilepsy (78%)
Interventions Monotherapy with oxcarbazepine or phenytoin. Eight-week titration period started with
150 mg OXC or 50 mg PHT, increased bi-weekly, based on clinical response
After 8 weeks participants were to be on a tid regimen with daily doses of 450 mg to
2400 mg OXC or 150 mg to 800 mg PHT
Continued during 48-week maintenance with adjustment according to clinical response
A third long-term, open-label extension phase followed themaintenance period.Double-
blind results only are reported
Outcomes Efficacy: proportion of seizure-free participants who had at least 1 seizure assessment
during the maintenance period
Tolerability: comparison of participants who prematurely discontinued because of ad-
verse experiences
Clinical utility: comparing the rate of premature discontinuation
Notes IPD provided for all outcomes of the review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment groups randomised in 1:1 ratio
across centres via computer-generated ran-
domisation numbers over balanced blocks
of size 6
Allocation concealment (selection bias) Low risk Allocation concealment was achieved with
sequentially numbered packages which
were identical and contained identical
tablets (informationprovided by trial statis-
tician)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Trial conducted in 2 phases: 56-week, dou-
ble-blind phase followed by long-term,
open-label extension
Double-blind phase results reported only
Blind achieved with divisible OXC and
PHT tablets identical in appearance
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Guerreiro 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates reported in both treat-
ment phases, participants withdrawing
from treatment were no longer followed
up so seizure outcomes had to be censored
at time of treatment failure and therefore
analyses for remission and seizure outcomes
could not adopt an ITT approach
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk No other sources of bias detected
1. Abbreviations: AED: antiepileptic drug; EEG: electroencephalogram; IPD: individual participant data; ITT: intention-to-treat;
OXC: oxcarbazepine; PHT: phenytoin; tid: three times per day
2. For studies where IPD were provided for all randomised participants (Bill 1997; Guerreiro 1997), attrition and reporting bias are
reduced as attrition rates and unpublished outcome data are requested.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Sabers 1995 Not fully randomised: “The treatment was chosen at random unless the individual diagnoses required a specific drug”
IPD: individual participant data
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D A T A A N D A N A L Y S E S
Comparison 1. Oxcarbazepine versus phenytoin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to treatment failure (any
reason related to the treatment)
2 480 Hazard Ratio (Fixed, 95% CI) 0.77 [0.53, 1.12]
2 Time to treatment failure due to
adverse events
2 480 Hazard Ratio (Fixed, 95% CI) 0.22 [0.10, 0.51]
3 Time to treatment failure due to
lack of efficacy
2 480 Hazard Ratio (Fixed, 95% CI) 1.17 [0.31, 4.35]
4 Time to treatment failure (any
reason related to the treatment)
- by epilepsy type
2 476 Hazard Ratio (Fixed, 95% CI) 0.78 [0.53, 1.14]
4.1 Focal onset seizures 2 333 Hazard Ratio (Fixed, 95% CI) 0.69 [0.43, 1.09]
4.2 Generalised onset seizures 2 143 Hazard Ratio (Fixed, 95% CI) 1.03 [0.51, 2.08]
5 Time to treatment failure (any
reason related to treatment)
- sensitivity analysis: epilepsy
type reclassified to focal onset
for generalised onset and age >
30 years
2 476 Hazard Ratio (Fixed, 95% CI) 0.77 [0.52, 1.13]
5.1 Focal onset seizures 2 363 Hazard Ratio (Fixed, 95% CI) 0.80 [0.52, 1.24]
5.2 Generalised onset seizures 2 113 Hazard Ratio (Fixed, 95% CI) 0.67 [0.31, 1.46]
6 Time to treatment failure (any
reason related to treatment)
- sensitivity analysis: epilepsy
type reclassified to uncertain
seizure type for generalised
onset and age > 30 years
2 476 Hazard Ratio (Fixed, 95% CI) 0.73 [0.50, 1.08]
6.1 Focal onset seizures 2 333 Hazard Ratio (Fixed, 95% CI) 0.69 [0.43, 1.09]
6.2 Generalised onset seizures 2 113 Hazard Ratio (Fixed, 95% CI) 0.67 [0.31, 1.46]
6.3 Uncertain seizure type 1 30 Hazard Ratio (Fixed, 95% CI) 6.23 [0.73, 53.44]
7 Time to first seizure 2 472 Hazard Ratio (Fixed, 95% CI) 0.93 [0.72, 1.21]
8 Time to first seizure - by epilepsy
type
2 468 Hazard Ratio (Fixed, 95% CI) 0.97 [0.75, 1.26]
8.1 Focal onset seizures 2 326 Hazard Ratio (Fixed, 95% CI) 0.92 [0.68, 1.25]
8.2 Generalised onset seizures 2 142 Hazard Ratio (Fixed, 95% CI) 1.11 [0.66, 1.86]
9 Time to achieve 12-month
remission
2 472 Hazard Ratio (Fixed, 95% CI) 1.09 [0.80, 1.47]
10 Time to achieve 12-month
remission - by epilepsy type
2 468 Hazard Ratio (Fixed, 95% CI) 1.04 [0.77, 1.41]
10.1 Focal onset seizures 2 326 Hazard Ratio (Fixed, 95% CI) 1.09 [0.75, 1.57]
10.2 Generalised onset
seizures
2 142 Hazard Ratio (Fixed, 95% CI) 0.94 [0.55, 1.62]
11 Time to achieve 6-month
remission
2 472 Hazard Ratio (Fixed, 95% CI) 1.12 [0.87, 1.43]
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12 Time to achieve 6-month
remission - by epilepsy type
2 468 Hazard Ratio (Fixed, 95% CI) 1.06 [0.82, 1.36]
12.1 Focal onset seizures 2 326 Hazard Ratio (Fixed, 95% CI) 1.17 [0.87, 1.58]
12.2 Generalised onset
seizures
2 142 Hazard Ratio (Fixed, 95% CI) 0.83 [0.53, 1.31]
Analysis 1.1. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 1 Time to treatment failure (any
reason related to the treatment).
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 1 Time to treatment failure (any reason related to the treatment)
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Bill 1997 143 144 -0.1229583 (0.232981) 66.6 % 0.88 [ 0.56, 1.40 ]
Guerreiro 1997 97 96 -0.533935 (0.3293258) 33.4 % 0.59 [ 0.31, 1.12 ]
Total (95% CI) 240 240 100.0 % 0.77 [ 0.53, 1.12 ]
Heterogeneity: Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours OXC Favours PHT
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Analysis 1.2. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 2 Time to treatment failure due to
adverse events.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 2 Time to treatment failure due to adverse events
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Bill 1997 143 144 -1.273365 (0.5055685) 69.1 % 0.28 [ 0.10, 0.75 ]
Guerreiro 1997 97 96 -1.992214 (0.7561033) 30.9 % 0.14 [ 0.03, 0.60 ]
Total (95% CI) 240 240 100.0 % 0.22 [ 0.10, 0.51 ]
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00037)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours OXC Favours PHT
Analysis 1.3. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 3 Time to treatment failure due to
lack of efficacy.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 3 Time to treatment failure due to lack of efficacy
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Bill 1997 143 144 -0.0537876 (1.414327) 22.6 % 0.95 [ 0.06, 15.15 ]
Guerreiro 1997 97 96 0.2131499 (0.7642245) 77.4 % 1.24 [ 0.28, 5.53 ]
Total (95% CI) 240 240 100.0 % 1.17 [ 0.31, 4.35 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours OXC Favours PHT
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Analysis 1.4. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 4 Time to treatment failure (any
reason related to the treatment) - by epilepsy type.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 4 Time to treatment failure (any reason related to the treatment) - by epilepsy type
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Bill 1997 84 98 -0.1522087 (0.2952118) 43.9 % 0.86 [ 0.48, 1.53 ]
Guerreiro 1997 73 78 -0.7538293 (0.3843753) 25.9 % 0.47 [ 0.22, 1.00 ]
Subtotal (95% CI) 157 176 69.8 % 0.69 [ 0.43, 1.09 ]
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Generalised onset seizures
Bill 1997 58 46 -0.12511 (0.3936862) 24.7 % 0.88 [ 0.41, 1.91 ]
Guerreiro 1997 22 17 0.7424444 (0.8367559) 5.5 % 2.10 [ 0.41, 10.83 ]
Subtotal (95% CI) 80 63 30.2 % 1.03 [ 0.51, 2.08 ]
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 237 239 100.0 % 0.78 [ 0.53, 1.14 ]
Heterogeneity: Chi2 = 3.34, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
0.01 0.1 1 10 100
Favours OXC Favours PHT
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Analysis 1.5. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 5 Time to treatment failure (any
reason related to treatment) - sensitivity analysis: epilepsy type reclassified to focal onset for generalised onset
and age > 30 years.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 5 Time to treatment failure (any reason related to treatment) - sensitivity analysis: epilepsy type reclassified to focal onset for generalised onset and age > 30
years
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Bill 1997 98 114 0.0524915 (0.2753115) 50.1 % 1.05 [ 0.61, 1.81 ]
Guerreiro 1997 73 78 -0.7538293 (0.3843753) 25.7 % 0.47 [ 0.22, 1.00 ]
Subtotal (95% CI) 171 192 75.9 % 0.80 [ 0.52, 1.24 ]
Heterogeneity: Chi2 = 2.91, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.99 (P = 0.32)
2 Generalised onset seizures
Bill 1997 44 30 -0.7298812 (0.4508335) 18.7 % 0.48 [ 0.20, 1.17 ]
Guerreiro 1997 22 17 0.7424444 (0.8367559) 5.4 % 2.10 [ 0.41, 10.83 ]
Subtotal (95% CI) 66 47 24.1 % 0.67 [ 0.31, 1.46 ]
Heterogeneity: Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 237 239 100.0 % 0.77 [ 0.52, 1.13 ]
Heterogeneity: Chi2 = 5.46, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.01 0.1 1 10 100
Favours OXC Favours PHT
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Analysis 1.6. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 6 Time to treatment failure (any
reason related to treatment) - sensitivity analysis: epilepsy type reclassified to uncertain seizure type for
generalised onset and age > 30 years.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 6 Time to treatment failure (any reason related to treatment) - sensitivity analysis: epilepsy type reclassified to uncertain seizure type for generalised onset
and age > 30 years
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Bill 1997 84 98 -0.1522087 (0.2952118) 45.1 % 0.86 [ 0.48, 1.53 ]
Guerreiro 1997 73 78 -0.7538293 (0.3843753) 26.6 % 0.47 [ 0.22, 1.00 ]
Subtotal (95% CI) 157 176 71.8 % 0.69 [ 0.43, 1.09 ]
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Generalised onset seizures
Bill 1997 44 30 -0.7298812 (0.4508335) 19.4 % 0.48 [ 0.20, 1.17 ]
Guerreiro 1997 22 17 0.7424444 (0.8367559) 5.6 % 2.10 [ 0.41, 10.83 ]
Subtotal (95% CI) 66 47 25.0 % 0.67 [ 0.31, 1.46 ]
Heterogeneity: Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.00 (P = 0.32)
3 Uncertain seizure type
Bill 1997 14 16 1.83017 (1.096176) 3.3 % 6.23 [ 0.73, 53.44 ]
Subtotal (95% CI) 14 16 3.3 % 6.23 [ 0.73, 53.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 237 239 100.0 % 0.73 [ 0.50, 1.08 ]
Heterogeneity: Chi2 = 7.88, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 3.94, df = 2 (P = 0.14), I2 =49%
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Analysis 1.7. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 7 Time to first seizure.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 7 Time to first seizure
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Guerreiro 1997 96 94 -0.1657741 (0.2186012) 36.7 % 0.85 [ 0.55, 1.30 ]
Bill 1997 139 143 -0.0132779 (0.1663405) 63.3 % 0.99 [ 0.71, 1.37 ]
Total (95% CI) 235 237 100.0 % 0.93 [ 0.72, 1.21 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 8 Time to first seizure - by epilepsy
type.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 8 Time to first seizure - by epilepsy type
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Bill 1997 81 97 -0.0251235 (0.1984164) 45.4 % 0.98 [ 0.66, 1.44 ]
Guerreiro 1997 72 76 -0.1633135 (0.248943) 28.9 % 0.85 [ 0.52, 1.38 ]
Subtotal (95% CI) 153 173 74.3 % 0.92 [ 0.68, 1.25 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Generalised onset seizures
Bill 1997 57 46 0.1498876 (0.317424) 17.8 % 1.16 [ 0.62, 2.16 ]
Guerreiro 1997 22 17 0.0009293 (0.4750764) 7.9 % 1.00 [ 0.39, 2.54 ]
Subtotal (95% CI) 79 63 25.7 % 1.11 [ 0.66, 1.86 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.69)
Total (95% CI) 232 236 100.0 % 0.97 [ 0.75, 1.26 ]
Heterogeneity: Chi2 = 0.61, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
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Analysis 1.9. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 9 Time to achieve 12-month
remission.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 9 Time to achieve 12-month remission
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Bill 1997 139 143 0.0235502 (0.2089093) 54.7 % 1.02 [ 0.68, 1.54 ]
Guerreiro 1997 96 94 0.1604977 (0.2293838) 45.3 % 1.17 [ 0.75, 1.84 ]
Total (95% CI) 235 237 100.0 % 1.09 [ 0.80, 1.47 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 10 Time to achieve 12-month
remission - by epilepsy type.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 10 Time to achieve 12-month remission - by epilepsy type
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Bill 1997 81 97 0.0288855 (0.2752771) 31.9 % 1.03 [ 0.60, 1.77 ]
Guerreiro 1997 72 76 0.1297118 (0.2580061) 36.3 % 1.14 [ 0.69, 1.89 ]
Subtotal (95% CI) 153 173 68.2 % 1.09 [ 0.75, 1.57 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Generalised onset seizures
Bill 1997 57 46 -0.123917 (0.3230557) 23.2 % 0.88 [ 0.47, 1.66 ]
Guerreiro 1997 22 17 0.1146865 (0.5281098) 8.7 % 1.12 [ 0.40, 3.16 ]
Subtotal (95% CI) 79 63 31.8 % 0.94 [ 0.55, 1.62 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 232 236 100.0 % 1.04 [ 0.77, 1.41 ]
Heterogeneity: Chi2 = 0.40, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 1.11. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 11 Time to achieve 6-month
remission.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 11 Time to achieve 6-month remission
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Bill 1997 139 143 0.0635714 (0.1655838) 58.2 % 1.07 [ 0.77, 1.47 ]
Guerreiro 1997 96 94 0.1756976 (0.1952146) 41.8 % 1.19 [ 0.81, 1.75 ]
Total (95% CI) 235 237 100.0 % 1.12 [ 0.87, 1.43 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Oxcarbazepine versus phenytoin, Outcome 12 Time to achieve 6-month
remission - by epilepsy type.
Review: Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Oxcarbazepine versus phenytoin
Outcome: 12 Time to achieve 6-month remission - by epilepsy type
Study or subgroup Oxcarbazepine Phenytoin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset seizures
Bill 1997 81 97 0.1412269 (0.2118206) 36.1 % 1.15 [ 0.76, 1.74 ]
Guerreiro 1997 72 76 0.1825448 (0.218882) 33.8 % 1.20 [ 0.78, 1.84 ]
Subtotal (95% CI) 153 173 69.8 % 1.17 [ 0.87, 1.58 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Generalised onset seizures
Bill 1997 57 46 -0.2259464 (0.270217) 22.2 % 0.80 [ 0.47, 1.35 ]
Guerreiro 1997 22 17 -0.0707107 (0.4498349) 8.0 % 0.93 [ 0.39, 2.25 ]
Subtotal (95% CI) 79 63 30.2 % 0.83 [ 0.53, 1.31 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
Total (95% CI) 232 236 100.0 % 1.06 [ 0.82, 1.36 ]
Heterogeneity: Chi2 = 1.66, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.56, df = 1 (P = 0.21), I2 =36%
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A D D I T I O N A L T A B L E S
Table 1. Reasons for premature discontinuation (treatment failure)
Reason
for early ter-
mination
Bill 1997 Guerreiro 1997 Total
OXC PHT OXC PHT OXC PHT All
Adverse events
(Event)a
5 18 2 14 7 32 39
Lack of effi-
cacy (Event)
1 1 4 3 5 4 9
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Table 1. Reasons for premature discontinuation (treatment failure) (Continued)
Non-compli-
ance/pro-
tocol violation
(Event)
29 20 9 7 38 27 65
Ill-
ness or death
(not treatment
related,
censored)b
2 5 1 0 3 5 8
Lost to follow-
up (censored)
19 17 8 9 27 26 53
Other
(censored)c
0 0 0 1 0 1 1
Completed
the study (cen-
sored)
87 83 73 62 160 145 305
Total 143 144 97 96 240 240 480
a. One participant on phenytoin (in Bill 1997) had an episode of status epilepticus following non-compliance with treatment and died.
This was classified as a serious adverse event (’Event’) in the analysis of time to treatment failure.
b. One participant (in Bill 1997) died after getting caught up in political violence. This was deemed to not be related to treatment and
was censored in the analysis of time to treatment failure.
c. One participant (in Guerreiro 1997) immediately withdrew from treatment at baseline (following randomisation). This was deemed
to not be related to treatment and was censored in the analysis of time to treatment failure.
Table 2. Demographic characteristics of trial participants (trials providing individual participant data)
Bill 1997 Guerreiro 1997
OXC PHT Missing OXC PHT Missing
Focal seizures: n
(%)
84 (59%) 98 (68%) 1 73 (77%) 78 (82%) 3
Male gender: n
(%)
82 (57%) 92 (64%) 0 46 (47%) 50 (52%) 0
Age at en-
try (years): mean
(SD), range
27.1 (11.3),
16 to 63
26.5 (10.2),
15 to 91
1 10.2 (3.1),
5 to 17
10.9 (3.1),
6 to 17
0
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Table 2. Demographic characteristics of trial participants (trials providing individual participant data) (Continued)
Aged
> 30 and gener-
alised seizures: n
(%)
14 16 1 NA NA NA
Epilepsy
duration (years):
mean (SD),
range
1.8 (3.7), 0 to 22 1.7 (3.7), 0 to 25 0 0.6 (0.9), 0 to 5 0.7 (1.8), 0 to 14 0
Num-
ber of seizures in
prior 6 months:
median (range)
3 (0 to 252) 3 (0 to 157) 0 2 (0 to 70) 2 (0 to 108) 0
EEG normal: n
(%)
82 (60%) 70 (49%) 9 49 (51%) 52 (54%) 0
CT scan normal:
n (%)
31 (27%) 38 (30%) 45 6 (8%) 6 (9%) 55
CT= computerised tomography; EEG = electroencephalographic; n = number of participants; NA = not available; OXC=oxcarbazepine;
PHT= Phenytoin; SD = standard deviation
Proportions (%) are calculated based on non-missing data
Table 3. Number of participants contributing to analysis
Trial
Epilepsy
type
Number
randomised
Time to treat-
ment failurea
Time to first
seizure
Time to 12month
remission
Time to 6 month remission
OXC PHT OXC PHT OXC PHT OXC PHT OXC PHT
Bill
1997
Focal 84 98 84 98 81 97 81 97 81 97
Gener-
alised
58 46 59 46 58 46 58 46 58 46
Total
classified
142 144 142 144 138 143 138 143 138 143
Unclas-
sified/
missing
1 0 1 0 1 0 1 0 1 0
TOTAL 143 144 143 144 139 143 139 143 139 143
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Table 3. Number of participants contributing to analysis (Continued)
Guer-
reiro
1997
Focal 73 78 73 78 72 76 72 76 72 76
Gener-
alised
22 17 22 17 22 17 22 17 22 17
Total
classified
95 95 95 95 94 93 94 93 94 93
Unclas-
sified/
missing
2 1 2 1 2 1 2 1 2 1
TOTAL 97 96 97 96 96 94 96 94 96 94
TOTAL 237 239 237 239 235 237 235 237 235 237
OXC: oxcarbazepine, PHT: phenytoin
a. All participants were included in analyses of time to treatment failure for any reason related to the treatment, time to treatment
failure due to adverse events and time to treatment failure due to lack of efficacy.
Table 4. Results of sensitivity analyses
Analysisa Time to treatment
failure
(for any reason re-
lated to treatment)
Time to first
seizure
Time to 12-month
remission
Time to 6-month
remission
Original analysis
(adjusted for
epilepsy type)
Participants Overall:476
(Foc: 333; Gen:
143)
Overall: 468
(Foc: 326; Gen:
142)
Overall: 468
(Foc: 326; Gen:
142)
Overall: 468
(Foc: 326; Gen:
142)
Pooled HR
(95% CI),
P value,
I² (%)
Foc: 0.69 (0.43 to 1.
09)
P=0.11, I² = 35%
Gen: 1.03 (0.51 to
2.08)
P=0.93, I² = 0%
Overall: 0.78 (0.53
to 1.14)
P=0.20, I² = 10%
Foc: 0.92 (0.68 to 1.
25),
P=0.61, I² = 0%
Gen: 1.11 (0.66 to
1.86),
P=0.69, I² = 0%
Overall: 0.97 (0.75
to 1.26),
P=0.81, I² = 0%
Foc: 1.09 (0.75 to 1.
57),
P=0.66, I² = 0%
Gen: 0.94 (0.55 to
1.62),
P=0.83, I² = 0%
Overall: 1.04 (0.77
to 1.41), P=0.81, I²
= 0%
Foc: 1.17 (0.87 to 1.
58),
P=0.29, I² = 0%
Gen: 0.83 (0.53 to
1.31),
P=0.43, I² = 0%
Overall: 1.06 (0.82
to 1.36),
P=0.65, I² = 0%
Test of subgroup
differences
P = 0.34, I² = 0% P = 0.55, I² =0% P = 0.67, I² = 0% P = 0.21, I² = 35.8%
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Table 4. Results of sensitivity analyses (Continued)
Sensitivity analysis -
events in the
double-blind period
only
(events censored at
392 days - 56weeks)
b
Participants Overall:476
(Foc: 333; Gen:
143)
Unchanged from
original analysis
(no first
seizure events in the
open label phase)
Overall: 468
(Foc: 326; Gen:
142)
Unchanged from
original analysis
(no six-month re-
mission
events in the open
label phase)
Pooled HR
(95% CI),
P value,
I² (%)
Foc: 0.68 (0.43 to 1.
09)
P=0.11, I² = 34%
Gen: 0.92 (0.45 to
1.88)
P=0.82 I² = 0%
Overall: 0.75 (0.51
to 1.10)
P=0.14, I² = 0%
Foc: 1.19 (0.81 to 1.
76),
P = 0.37, I² = 0%
Gen: 0.92 (0.53 to
1.61),
P = 0.91, I² = 0%
Overall: 1.10 (0.80
to 1.51),
P = 0.57, I² = 0%
Test of subgroup
differences
P = 0.49, I² = 0% P = 0.46, I² = 0%
Sensitivity analysis
classifying
generalised onset
seizures
and age at onset > 30
classified as focal on-
set seizures
Participants Overall:476
(Foc: 363; Gen:
113)
Overall: 468
(Foc: 355; Gen:
113)
Overall: 468
(Foc: 355; Gen:
113)
Overall: 468
(Foc: 355; Gen:
113)
Pooled HR
(95% CI),
P value,
I² (%)
Foc: 0.80 (0.52 to 1.
24)
P=0.32, I² = 66%
Gen: 0.67 (0.31 to
1.46)
P=0.32, I² = 58%
Overall: 0.77 (0.52
to 1.13)
P=0.18, I² = 45%
Foc: 0.87 (0.65 to 1.
17),
P = 0.36, I² = 0%
Gen: 1.44 (0.79 to
2.62),
P = 0.23, I² = 0%
Overall: 0.97 (0.73
to 1.28),
P = 0.82, I² = 7%
Foc: 1.12 (0.79 to 1.
59),
P = 0.53, I² = 0%
Gen: 0.75 (0.40 to
1.41),
P = 0.37, I² = 0%
Overall: 1.02 (0.75
to 1.38),
P = 0.91, I² = 0%
Foc: 1.19 (0.90 to 1.
58),
P = 0.23, I² = 0%
Gen: 0.72 (0.43 to
1.23),
P = 0.23, I² = 0%
Overall: 1.06 (0.82
to 1.37),
P = 0.66, I² = 5%
Test of subgroup
differences
P = 0.70, I² = 0% P = 0.14, I² = 54% P = 0.28, I² = 14.9% P = 0.10, I² = 62.4%
Sensitivity analysis
classifying
generalised onset
seizures and
age at onset > 30
classified as uncer-
tain epilepsy type
Participants Overall:476
(Foc: 333; Gen:
113; Unc: 30)
Overall: 468
(Foc: 326; Gen:
113; Unc: 29)
Overall: 468
(Foc: 326; Gen:
113; Unc: 29)
Overall: 468
(Foc: 326; Gen:
113; Unc: 29)
Pooled HR
(95% CI),
P value,
Foc: 0.69 (0.43 to 1.
09)
P=0.11, I² = 35%
Foc: 0.92 (0.68 to 1.
25),
P=0.61, I² = 0%
Foc: 1.09 (0.75 to 1.
57),
P=0.66, I² = 0%
Foc: 1.17 (0.87 to 1.
58),
P=0.29, I² = 0%
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Table 4. Results of sensitivity analyses (Continued)
I² (%) Gen: 0.67 (0.31 to
1.46)
P=0.32, I² = 58%
Unc: 6.23 [0.73, 53.
44]
P=0.09, I² = NA%
Overall: 0.73 [0.50,
1.08]
P=0.12, I² = 49%
Gen: 1.44 (0.79 to
2.62),
P = 0.23, I² = 0%
Unc: 0.38 (0.10 to
1.44),
P=0.16, I² =NA
Overall: 0.97 (0.75
to 1.27),
P=0.85, I² =18%
Gen: 0.75 (0.40 to
1.41),
P = 0.37, I² = 0%
Unc: 2.05 (0.68 to
6.17),
P = 0.20, I² = NA
Overall: 1.05 (0.77
to 1.42),
P = 0.77, I² = 0%
Gen: 0.72 (0.43 to
1.23),
P = 0.23, I² = 0%
Unc: 1.51 (0.59 to
3.86),
P=0.40, I² = NA
Overall: 1.07 (0.83
to 1.38),
P = 0.48, I² = 0%
Test of subgroup
differences
P = 0.14, I² = 49.2% P = 0.16, I² = 45.5% P = 0.77, I² = 21.4% P = 0.22, I² = 33.2%
CI: confidence interval; Foc: focal onset seizures; Gen=generalised onset seizures; HR: hazard ratio; NA:Not applicable, Unc= uncertain
seizure type.
a. For time to treatment failure and time to first seizure, HR < 1 indicates a clinical advantage for oxcarbazepine and for time to 12-
month and 6-month remission, HR < 1 indicates a clinical advantage for phenytoin. All results presented are calculated from fixed-
effect meta-analysis.
b. Five participants with time to treatment failure greater than 392 days (within open-label treatment phase); two with generalised
epilepsy and three with focal epilepsy. Fifteen participants with time to 12-month remission greater than 392 days (within open-label
treatment phase); three with generalised epilepsy and 12 with focal epilepsy. No participants with six-month remission achieved or first
seizure recorded in the open-label treatment phase.
Table 5. Adverse events reported
Adverse event Bill 1997 Guerreiro 1997 Total
OXC PHT OXC PHT OXC PHT Total
Somnolence 41 41 24 28 65 69 134
Headache 20 27 13 14 33 41 74
Dizziness 18 22 9 21 27 43 70
Gum Hyper-
plasia
2 18 2 24 4 42 46
Nausea 13 16 5 7 18 23 41
Rash 12 16 4 5 16 21 37
Nervousness 2 9 2 11 4 20 24
Apathy 0 0 11 10 11 10 21
Tremor 4 10 0 0 4 10 14
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Table 5. Adverse events reported (Continued)
Ataxia 0 0 0 13 0 13 13
Diplopia 1 11 0 0 1 11 12
Acne 9 3 0 0 9 3 12
Nystagmus 3 8 0 0 3 8 11
Abnormal
thinking
0 0 5 6 5 6 11
Abdominal
pain
0 0 5 4 5 4 9
Hypertricosis 0 0 0 8 0 8 8
Vomiting 0 0 0 5 0 5 5
A P P E N D I C E S
Appendix 1. CRS Web search strategy
1. MeSH DESCRIPTOR Phenytoin AND CENTRAL:TARGET
2. (Difenilhidantoin* or Dihydantoin or Dilantin or Diphenylan or Diphenylhydantoin* or Diphenylhydatanoin* or Dwufenylo-
hydantoin* or Epanutin or Eptoin or Fenitoin* or Fenytoin* or Phenytek or Phenytoin*):AB,KW,MC,MH,TI AND CENTRAL:
TARGET
3. #1 OR #2 AND CENTRAL:TARGET
4. (oxcarbazepi* or carbox or OCBZ or oxcarbamaz* or trilept*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
5. #3 AND #4 AND >22/01/2013:CRSCREATED AND CENTRAL:TARGET
6. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
7. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
8. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
9. #6 OR #7 OR #8 AND CENTRAL:TARGET
10. #5 AND #9
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Appendix 2. MEDLINE search strategy
The following search is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE
(Lefebvre 2011).
1. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
2. clinical trials as topic.sh.
3. trial.ti.
4. 1 or 2 or 3
5. exp animals/ not humans.sh.
6. 4 not 5
7. exp Epilepsy/
8. exp Seizures/
9. (epilep$ or seizure$ or convuls$).tw.
10. 7 or 8 or 9
11. exp Phenytoin/
12. (Difenilhidantoin$ or Dihydantoin or Dilantin or Diphenylan or Diphenylhydantoin$ or Diphenylhydatanoin$ or Dwufenylo-
hydantoin$ or Epanutin or Eptoin or Fenitoin$ or Fenytoin$ or Phenytek or Phenytoin$).tw.
13. (oxcarbazepi$ or carbox or OCBZ or oxcarbamaz$ or trilept$).tw.
14. (11 or 12) and 13
15. 6 and 10 and 14
16. limit 15 to ed=20130122-20180820
17. 15 not (1$ or 2$).ed.
18. 17 and (2013$ or 2014$ or 2015$ or 2016$ or 2017$ or 2018$).dt.
19. 16 or 18
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | Oxcarbazepine AND phenytoin
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: oxcarbazepine AND phenytoin
Recruitment status: all
Phases: 2, 3, 4
WH A T ’ S N E W
Date Event Description
20 August 2018 New search has been performed Searches updated 20 August 2018; we included no new
studies and the conclusions are unchanged
1 August 2018 New citation required but conclusions have not changed The term “partial” has been replaced by “focal”, in ac-
cordance with the most recent classification of epilepsies
of the International League Against Epilepsy (Scheffer
2017).
The lead author, previously Sarah Nolan, is now Sarah
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(Continued)
Nevitt
H I S T O R Y
Protocol first published: Issue 2, 2002
Review first published: Issue 2, 2006
Date Event Description
10 February 2015 New search has been performed Searches updated 3 February 2013; no new studies
identified. Conclusions unchanged
11 December 2014 Amended Title changed to specify that the review uses individual
participant data
12 March 2013 New search has been performed Searches updated 22 January 2013; one new trial in-
cluded (Aikia 1992). Conclusions remain unchanged.
22 January 2013 New citation required but conclusions have not
changed
Analyses and text updated. ’Risk of bias’ assessments
and ’Summary of findings’ table added
7 September 2010 Amended Contact author’s details updated.
7 August 2009 Amended Copy edits made at editorial base.
24 October 2008 Amended Search strategy amended to comply with RevMan 5.
12 August 2008 New search has been performed Searches were re-run on 4 April 2008; no new studies
were found
12 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
SJ Nevitt assessed studies for inclusion in the review update, obtained individual participant data from trial investigators for the review
update, assessed risk of bias in all included studies, performed analyses in Stata version 14, added survival plots and a ’Summary of
findings’ table, and updated the text of the review.
M Muller was the lead investigator on the original review and was involved in developing the original protocol, assessing eligibility
of trials for inclusion in the review and obtaining, validating and checking individual participant data and assessing risk of bias in all
included studies.
C Tudur Smith provided statistical supervision and was involved with data analysis in the original review.
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AG Marson was involved in obtaining individual participant data from original trial investigators and provided guidance with the
clinical interpretation of results
D E C L A R A T I O N S O F I N T E R E S T
SJN: none known.
CTS: none known.
AGM: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in
Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by the National Institute
for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
S O U R C E S O F S U P P O R T
Internal sources
• University of Liverpool, UK.
• South African Cochrane Centre, Medical Research Council, South Africa.
• Biostatistics Unit, Medical Research Council, South Africa.
• Institute for Maritime Technology, Simon’s Town, South Africa.
External sources
• Effective Health Care Alliance, UK.
• National Health Service, Research and Development, UK.
• Department for International Development, UK.
• National Institute of Health Research (NIHR), UK.
This review presents independent research commissioned by the National Institute for Health Research (NIHR). The views expressed
in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the 2013 update, we added sensitivity analyses for misclassification of epilepsy type following the discovery of this potential
classification bias in other reviews in the series of Cochrane IPD reviews investigating pair-wise monotherapy comparisons. We added
’Summary of findings’ tables and added text in the Methods section for ’Summary of findings’ tables.
In December 2014 we changed the title to specify that the review uses individual participant data.
In the 2018 update, we added the outcome ’incidence of adverse events’ and removed the outcome ’quality of Life’, for consistency
with the other reviews in the series of Cochrane IPD reviews investigating pair-wise monotherapy comparisons.
In the 2018 update, we redefined ’time to withdrawal of allocated treatment’ as ’time to treatment failure’, due to feedback received from
the Cochrane Editorial Unit regarding potential confusion regarding ’withdrawal’ as a positive or negative outcome of antiepileptic
monotherapy. The definitions of reasons for treatment failure/withdrawal for some individuals were reclassified as events or censored
observations in line with the definitions of a treatment related treatment failure used across the series of Cochrane IPD reviews
investigating pair-wise monotherapy comparisons.
We added analyses of ’time to treatment failure’ (due to lack of efficacy and due to adverse events) following feedback on published
antiepileptic drug monotherapy reviews that these sub-outcomes would be useful for clinical practice.
We replaced the term ’partial’ with ’focal’, in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (Scheffer 2017).
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N O T E S
Sarah J Nolan (lead author of the 2013 update) is now Sarah J Nevitt.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [∗therapeutic use]; Carbamazepine [∗analogs&derivatives; therapeutic use]; Epilepsies, Partial [drug therapy]; Epilepsy
[∗drug therapy]; Induction Chemotherapy; Phenytoin [∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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